

# Childhood Cancer Registry Sri Lanka



**National Cancer Control Programme**  
**Ministry of Health**  
Sri Lanka



# Childhood Cancer Registry

## Sri Lanka



National Cancer Control Programme,  
555/5, Public Health Complex,  
Elvitigala Mawatha,  
Narahenpita, Colombo 5,

1<sup>st</sup> Publication – Childhood Cancer Registry Sri Lanka

Published in November 2021

ISBN No. 978-624-5719-21-1

**Compiled by**

Strategic Information Management (SIM) Unit  
National Cancer Control Programme  
Ministry of Health

**Published by**



National Cancer Control Programme,  
Ministry of Health,  
555/5, Public Health Complex,  
Elvitigala Mawatha,  
Narahenpita, Colombo 05,  
Sri Lanka.

Contact No +94 112368627, Fax +94 112368627

Email- [nccpsl@yahoo.com](mailto:nccpsl@yahoo.com)

Web – [www.nccp.health.gov.lk](http://www.nccp.health.gov.lk)



National Cancer Control Programme, Sri Lanka

Printed by:

MS Solutions (Pvt)Ltd.

96 A, Temple Road,

Maharagama.

## Table of Contents

Description	Pages
List of Tables	5
List of Figures	7
Message from Director General of Health Services	9
Message from Deputy Director General (Non-Communicable Diseases)	11
Message from WHO Country Representative	13
Message from Director National Cancer Control Programme	15
Contributors	17
Executive Summary	19
Infographic	21
Introduction	23
Methodology	24
National Cancer Registry	25
Population Based Cancer Registry	69
Hospital Based Cancer Registry	73
Pathology Laboratory Based Cancer Registry	89
Mortality of childhood cancers based on existing evidence of 'Civil Registration System in Sri Lanka	95
Way forward	101
References	102



## List of Tables

Table No:	Description	Pages
Table 01:	Distribution of 0-19years old childhood cancer patients by sex in Sri Lanka 1985-2019	27
Table 02:	Crude incidence rate per 1,000,000 and Age standardized incidence rate per 1,000,000 among 0-19 years old childhood cancer patients by sex in Sri Lanka 2005 -2019	30
Table 03:	Childhood cancer incidence among 0-19 years males by 5year age groups in Sri Lanka 2015-2019	32
Table 04:	Childhood cancer incidence among 0-19 years females by 5year age groups in Sri Lanka 2015-2019	33
Table 05:	Childhood cancer incidence among 0-19 years Males by 5year age group in Sri Lanka 2015 according to ICCC-3	36
Table 06:	Childhood cancer incidence among 0-19 years Females by 5year age group in Sri Lanka 2015 according to ICCC-3	37
Table 07:	Childhood cancer incidence among 0-19 years Males by 5year age group in Sri Lanka 2016 according to ICCC-3	38
Table 08:	Childhood cancer incidence among 0-19 years Females by 5year age group in Sri Lanka 2016 according to ICCC-3	39
Table 09:	Childhood cancer incidence among 0-19 years Males by 5year age group in Sri Lanka 2017 according to ICCC-3	40
Table 10:	Childhood cancer incidence among 0-19 years Females by 5year age group in Sri Lanka 2017 according to ICCC-3	41
Table 11:	Childhood cancer incidence among 0-19 years Males by 5year age group in Sri Lanka 2018 according to ICCC-3	42
Table 12:	Childhood cancer incidence among 0-19 years Females by 5year age group in Sri Lanka 2018 according to ICCC-3	43
Table 13:	Childhood cancer incidence among 0-19 years Males by 5year age group in Sri Lanka 2019 according to ICCC-3	44
Table 14:	Childhood cancer incidence among 0-19 years Females by 5year age group in Sri Lanka 2019 according to ICCC-3	45
Table 15:	Distribution of WHO GICC index cancers	46
Table 16:	Distribution of childhood cancers among 0-19 years in 2015 – 2019 according to district	52
Table 17:	Childhood cancer incidence data (0-19) Male, Sri Lanka 2015 - 2019	53
Table 18:	Childhood cancer incidence data (0-19) Female, Sri Lanka 2015 - 2019	61
Table 19:	Distribution of incidence of 0-19 year old childhood cancer patients by 5 year age groups in Colombo district 2012 -2019	71
Table 20:	Distribution of deaths of 0-19 year old childhood cancer patients by 5 year age groups in Colombo district 2012 -2019	71

## List of Tables

<b>Table No:</b>	<b>Description</b>	<b>Pages</b>
Table 21:	Childhood and adolescent cancer incidence data by sex and site, National Cancer Institute, Maharagama 2020	75
Table 22:	Childhood and adolescent cancer incidence data (0-19) Male - National Cancer Institute Maharagama 2020	77
Table 23:	Childhood and adolescent cancer incidence data (0-19) Female, National Cancer Institute Maharagama 2020	82
Table 24:	Distribution of childhood cancers among 0-19 years - National Cancer Institute Sri Lanka (Apeksha Hospital) in 2020 according to district	86
Table 25:	Distribution of childhood cancer deaths occurred at National Cancer Institute by sex and 5 year age groups in year 2020	87
Table 26:	Distribution of childhood cancer deaths occurred at National Cancer Institute by sex and ICCC -3 categories in year 2020	88
Table 27:	Childhood cancer cases in ICCC code and histology by sex in 2020 - Lady Ridgway Children	90
Table 28:	Childhood cancer cases by sex in 2020 - Sirimavo Bandaranayake Children Hospital	94
Table 29:	Distribution of Cancer related deaths among 0-19 males & females by 5 year age groups in Sri Lanka 2010-2014	97
Table 30:	Distribution of childhood cancer deaths by ICD 10 site among 0-19 year old males for year 2010-2014	98
Table 31:	Distribution of Childhood Cancer related deaths among 0-19 year old females in year 2010-2014	99

## List of Figures

Figure No:	Description	Pages
Figure 1:	Number of 0-19 years newly diagnosed childhood cancer patients by sex in Sri Lanka, 2005-2019	28
Figure 2:	Number of newly diagnosed cancer patients 0-19 years and 20 years above in Sri Lanka, 2005 - 2019	28
Figure 3:	Age specific incidence rate of cancers in Sri Lanka - 2019	29
Figure 4:	Crude incidence rate of childhood cancer (0-19 years) in Sri Lanka 2005-2019	31
Figure 5:	Age standardized incidence rate of childhood cancers (0-19 years) in Sri Lanka 2005-2019	31
Figure 6:	Age specific incidence rate per 1,000,000 among 00-04 year old childhood cancer patients by sex in Sri Lanka 2005 -2019	34
Figure 7 :	Age specific incidence rate per 1,000,000 among 05-09 year old childhood cancer patients by sex in Sri Lanka 2005 -2019	34
Figure 8 :	Age specific incidence rate per 1,000,000 among 10-14year old childhood cancer patients by sex in Sri Lanka 2005 -2019	35
Figure 9:	Age specific incidence rate per 1,000,000 among 15-19 year old childhood cancer patients by sex in Sri Lanka 2005 -2019	35
Figure 10:	Leading cancers by 00 - 04 year age group among Males in Sri Lanka 2015-2019	48
Figure 11:	Leading cancers by 00 - 04 year age group among Females in Sri Lanka 2015-2019	48
Figure 12:	Leading cancers by 05 - 09 year age group among Males in Sri Lanka 2015-2019	49
Figure 13:	Leading cancers by 05 - 09 year age group among Females in Sri Lanka 2015-2019	49
Figure 14:	Leading cancers by 10-14 year age group among Males in Sri Lanka 2015-2019	50
Figure 15:	Leading cancers by 10-14 year age group among Females in Sri Lanka 2015-2019	50
Figure 16:	Leading cancers by 15-19 year age group among Males in Sri Lanka 2015-2019	51
Figure 17:	Leading cancers by 15-19 year age group among Females in Sri Lanka 2015-2019	51
Figure 18 :	Crude incidence rate & Crude mortality rate for 0-19 year old Childhood cancers in Colombo district, Sri Lanka 2012-2019	72
Figure 19 :	Age standardized incidence rate & mortality rate for 0-19 year old Childhood cancers in Colombo district, Sri Lanka 2012-2019	72
Figure 20:	Proportion of childhood and adolescent cancers in males, in National Cancer Institute Maharagama 2020	76
Figure 21:	Proportion of childhood and adolescent cancers in females, in National Cancer Institute Maharagama 2020	76
Figure 22:	Number of Childhood & Adolescent Cancer Related deaths among 0-19 year old males and females in Sri Lanka 2010 -2014	97
Figure 23:	Crude mortality rate for childhood cancer deaths by sex among 0-19 year patients in Sri Lanka 2010 -2014	100
Figure 24:	Age standardized mortality rate for childhood cancer deaths by sex among 0-19 year patients in Sri Lanka 2010 - 2014	100





## Message from the Director General of Health Services



I would like to send this message for the publication named 'Childhood Cancer Registry Sri Lanka', published by the National Cancer Control Programme of Ministry of Health.

World Health Organization has launched Global Initiative on Childhood Cancer (GICC) as one of the priority interventions related to cancer control towards achieving Sustainable Development Goals (SDG) and encourage member countries to achieve at least 60% survival rate for children with cancer by 2030 while reducing suffering due to cancers. Sri Lanka was selected as one of the pioneering countries to implement interventions to achieve above objectives. Therefore, Ministry of Health has taken the leadership in partnership with WHO country office and other stakeholders to strengthen childhood cancer care in Sri Lanka in systematic way. Most comprehensive up to date information on burden of childhood cancers in Sri Lanka is an essential resource material for planning, implementing, monitoring and evaluation of childhood cancer control programme.

The contributions of all stakeholders including the staff of NCCP, National Cancer Institute and Lady Ridgeway Hospital for children Colombo & Srimavo Bandaranayaka Children Hospital Peradeniya in developing this resource material are highly appreciated. In addition, the partnership of World Health Organization is highly appreciated.

**Dr. Asela Gunawardena**

Director General of Health Services



## Message from Deputy Director General (Non-Communicable Diseases)



I am happy to send this message to the publication named 'Childhood Cancer Registry Sri Lanka' published by the National Cancer Control Programme (NCCP) of Ministry of Health.

Sri Lanka is identified as one of the focus countries of Global Initiative of Childhood Cancers (GICC) and one of the initial activity is developing 5-year National Strategic Plan on Childhood & Adolescent Cancer Care for Sri Lanka. Comprehensive information on burden of paediatric cancers are essential in developing 5-year National Strategic Plan on Childhood & Adolescent Cancer Care in Sri Lanka. Since most of the information related to childhood cancer burden are available through the existing information pathways including National Cancer Registry Programme & Vital Registration System in Sri Lanka, revisiting those sources provide valuable information quickly. Therefore, this publication has generated most of the valuable information on burden of childhood cancers based on existing information available up to year 2020.

I hope policy makers, administrators, clinicians, researchers, academia and other interested groups will refer this publication for planning, implementation, monitoring and evaluation of interventions related to childhood cancer care in Sri Lanka. The hard work of National Cancer Control Programme & other stakeholders is highly appreciated for timely generation of this publication. The partnership of WHO Country office and other stakeholders were extremely contributed for completion of this activity successfully.

**Dr. Champika Wickramasingha**

MBBS, MSc, MD (Community Medicine)

Deputy Director General (Non-Communicable Diseases)



## Childhood Cancer Registry - Sri Lanka Message from the World Health Organization Representative to Sri Lanka



Childhood cancer patients comprise a special and understudied population of cancer patients. Of the estimated 400,000 children diagnosed with cancer each year, most live in low- and middle-income countries. For them, treatment is often unavailable or unaffordable. Only about 20–30% of those children survive, compared to more than 80% in high-income countries.

Cancer registries provide valuable sources of information regarding methods of diagnosis, stage distribution, treatment methods, response to treatment, and survival which form the basis for planning, implementation, monitoring and evaluation of interventions to improve the outcomes of cancers. However, health systems of many countries lack robust information system and good quality data on childhood cancers.

The World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) aims to improve outcomes for children with cancer around the world. The goal is to give all children with cancer the best chance to survive, to live full and abundant lives and to live and die without suffering. Strengthening evaluation and monitoring of childhood cancer data with quality assurance and robust information systems is one area of support to countries through this global initiative.

I am pleased that Sri Lanka is one of the countries supported by the GICC. The design of the childhood cancer registry in Sri Lanka supported by the GICC will serve as a useful monitoring tool of progress of achievements in relation to childhood cancers in the country and to plan, monitor and evaluate the interventions. I wish the information will be referred by policy makers, administrators, clinicians, researchers and civil society organizations for the betterment of childhood and adolescent cancer care in Sri Lanka. WHO is looking forward to the continuing partnership with Government of Sri Lanka and other key stakeholders in further strengthening the information systems and thereby the health systems towards better outcomes in childhood cancers in Sri Lanka.

**Dr. Alaka Singh**

WHO Country Representative for Sri Lanka



## Message from the Director National Cancer Control Programme



National Cancer Control Programme (NCCP) of Ministry of Health would like to release the first ever dedicated publication of Paediatric cancer registry of Sri Lanka.

Through the Global Initiative of Childhood Cancer, National Cancer Control Programme in partnership with World Health Organization (WHO) country office several interventions were commenced to strengthen childhood and adolescent cancer care. Developing 5-year National Strategic Plan on Childhood & Adolescent Cancer Care for Sri Lanka and commencing hospital based paediatric cancer registry were two of the identified activities. For these two activities, reviewing existing information sources on paediatric cancer burden is essential. Therefore, this publication was generated to fulfil that need.

Since follow up and survival information are not generated through the existing National Cancer Registry Programme, it is a timely need to commence a Hospital Based Cancer Registry. Therefore National Cancer Institute, Ministry of Health obtained the facility to utilize SJCARES cancer registry software for commencing Hospital Based Paediatric Cancer Registry through the membership of St.Jude Global Alliance for childhood cancer care.

I would like to appreciate the untiring effort of National Cancer Institute Maharagama ,Lady Ridgway Hospital for children and all other stakeholders for generating this publication and the partnership of WHO for making this effort a reality.

**Dr. Janaki Vidanapathirana**

MBBS, MSc, MD (Community Medicine)

Director, National Cancer Control Programme





## Contributors

### Coordinating team

#### National Cancer Control Programme

Dr. Janaki Vidanapathirana

Dr. Suraj Perera

Dr. A. Ziyad

Dr. DMS Manori

Dr. Chathurika Jayamani

Dr. K.G. Nirmala Jayanthi

Mrs. Chamila Peiris

#### National Cancer Institute

Dr. Vijith Gunasekara

Dr. Lalith Poddalgoda

Dr. Sanjeeva Gunasekara

Dr. Mahendra Somathilaka

Dr. Wasantha Rathnayaka

Dr. Thushari Hapuarachchi

Dr. Rukmal Gunathilaka

Dr. Niranjala Parakramadasa

#### Lady Ridgeway Hospital for Children

Dr. G. Wijesuriya

Dr. Sandini A Gunaratne

Dr. Chandima Thevarapperuma

#### Sirimavo Bandaranayake Specialized Children Hospital

Dr. A.M.S. Weerabandara

Dr. Chanuka Dharmadasa

Dr. Sujeewa Samaraweera

### Data extraction, entry & verification

Mrs. Nimesha Prasadi

Mrs. Nayomi Weerasingha

### Statistical analysis and report writing

Dr. Suraj Perera

Dr. Sanjeeva Gunasekara

Dr. K.G. Nirmala Jayanthi

Dr. D.M.S. Manori

Dr. Chathurika Jayamani

Mrs. Chamila Peiris

### Infographics

Dr. Chathurika Jayamani

Dr. Novandi Samarasingha

### Support staff

Mr. Saman Kumara Mahalekam

Mrs. Deepa Pathmanjali

Mrs. Thushari Dammika



## Executive Summary

Comprehensive, up to date information on burden of childhood cancers in Sri Lanka is an essential resource for planning, implementing, monitoring and evaluation of childhood cancer control programme in the country. This information will be helpful to identify the past and current status related to the childhood cancer and it will provide details of data gaps that exist in this field.

Therefore, existing evidence available through the (i) National Cancer Registry Programme, (ii) Population Based Cancer Registry of Colombo district, (iii) Hospital Based Cancer Registry of National Cancer Institute Sri Lanka (Apeksha Hospital, Maharagama), (iv) Pathology Laboratory Based Cancer Registries of Lady Ridgeway Hospital for Children, Colombo and Sirimavo Bandaranayake Memorial Children Hospital, Peradeniya (v) Civil Registration System of Sri Lanka were explored to identify the relevant information.

### **National Cancer Registry Programme**

Childhood cancer incidence data of 0 - 19 year old were available from year 1985 to 2019. In year 1985 a total of 283 (male-172 , female - 111) newly detected childhood cancers were reported in the country and in year 2019 a total of 780 (male-402 , female -378 ) childhood cancers were reported in the country. When the last 5 year (2015-2019) newly detected total number of childhood cancers were considered, on average about 828 childhood cancers were detected per year. Overall male: female ratio incidence of childhood cancer was nearly 1:1 (in 2019 male - 402, female - 378). The crude incidence rate of childhood cancers increased from 73.1 per 1,000,000 population (male – 75.2, female 70.9) in year 2005 to 107.3 per 1,000,000 (male -109.9, female - 104.7) in year 2019. Similarly, the age standardized incidence rate of childhood cancers increased from 73.1 per 1,000,000 population (male – 74.5, female 71.6) in year 2005 to 108.4 per 1,000,000 (male -111.5, female -105.1) in year 2019.

### **Population Based Cancer Registry – Colombo District**

The age standardized incidence rate of childhood cancers in Colombo district increased from 121.6 per 1,000,000 in year 2012 to 193.5 per 1,000,000 in year 2019. The age standardized mortality rate of childhood cancers in Colombo district increased from 17.3 per 1,000,000 in year 2012 to 27.1 per 1,000,000 in year 2019.

### **Hospital Based Cancer Registry- National Cancer Institute, Sri Lanka (Apeksha Hospital)**

A total of 550 newly detected 0-19 year childhood cancer patients were reported to National Cancer Institute in year 2020. Among males Leukaemias (51%), Bone tumours (11%), Lymphomas

(10%), CNS and brain tumours (9%) were the commonest cancers. Among females Leukaemia (41%), Germ cell tumours (11%) and CNS and brain tumours (11%) were the commonest cancers. A total 85 (male -49, female -36) childhood cancer deaths were reported and majority of deaths were due to leukaemias (63.5%, no.-54).

### **Pathology Laboratory Based Cancer Registry – Lady Ridgeway Hospital & Sirimavo Bandaranayake Memorial Hospital**

When pathology laboratory based cancer registries at histopathology and haematology settings were considered, a total of 91 childhood cancers were diagnosed at Lady Ridgeway hospital for Children in Colombo in year 2020 while 29 children with cancers were diagnosed at Siri Bandaranayake Memorial Hospital, Peradeniya.

### **Civil Registration System**


Cause specific death data is available upto year 2014. During the preceding 5 years (2010-2014) total number of childhood cancer deaths averaged around 263 (male -145, female -118) per year. The crude mortality rate of childhood cancers increased from 36.9 per 1,000,000 (male – 40.8, female 32.8) in year 2010 to 38.9 per 1,000,000 (male -43.1, female -34.6) in year 2014. Similarly, the age standardized incidence rate of childhood cancers increased from 36.8 per 1,000,000 population (male – 40.0, female -33.4) in year 2010 to 38.6 per 1,000,000 (male -42.7, female -34.5) in year 2014. The highest number of deaths due to childhood cancers occurred among males. Highest number of deaths due to childhood cancers occurred due to Leukemias (On average 37 % cancer deaths among males & 28% cancer deaths among females per year ) and Brain & central nervous system tumours ( on average 15% cancer deaths among males & 19% cancer deaths among females per year ).

Valid and reliable survival data related to the childhood cancers were not available through the existing information system. Therefore, Hospital Based Childhood Cancer Registry & Population Based Cancer Registry need to generate survival data as a short-term strategy. As a long term measure National Cancer Registry should be strengthened to generate national survival data for childhood cancers. In addition, civil registration system needs to be strengthened to generate timely, valid and reliable national childhood cancer mortality data.




# Childhood Cancer

## Male



- Leukemias
- Lymphomas
- CNS and brain tumors
- Neuroblastoma and other PNS tumors
- Retinoblastoma
- Renal tumours
- Hepatic tumours
- Bone tumours
- Soft tissue tumors
- Germ cell tumours
- Epithelial neoplasms
- Other and unspecified


## Female



Proportion of newly detected childhood cancers in males, 2020 (n=303)


Proportion of newly detected childhood cancers in females, 2020 (n=247)

(Ref: Hospital Based Cancer Registry, National Cancer Institute, Maharagama)




Number of newly diagnosed childhood cancer patients by sex in Sri Lanka, 2005-2019

(Ref: National Cancer Registry, Sri Lanka)



Crude incidence rate of childhood cancer (0-19 years) in Sri Lanka 2005-2019





Age standardized incidence rate of childhood cancers (0-19 years) in Sri Lanka 2005-2019

(Ref: National Cancer Registry, Sri Lanka)



## Mortality of childhood cancers in Sri Lanka




Number of Childhood & Adolescent Cancer Related deaths among 0-19 year old males and females in Sri Lanka 2010 -2014

Age standardized mortality rate for childhood cancer deaths by sex among 0-19 year patients in Sri Lanka 2010 - 2014

(Ref: Civil Registration System, Department of Census and Statistics)



## Incidence and Mortality of childhood cancer in Colombo District



Age standardized incidence rate & mortality rate for 0-19 year old Childhood cancers in Colombo district, Sri Lanka 2012-2019

(Ref: Population Based Cancer Registry, Colombo District, 2012-2019)

# Childhood Cancer Registry Sri Lanka

## Introduction

Cancers occurring up to 19 years of age are considered as childhood cancers. Though childhood cancer is not common as adult cancer, it is a leading cause of death among children worldwide. Most life-threatening childhood cancers can be effectively treated with modern multimodal treatment schedules leading to disease free survival.

Childhood cancer registries need to provide high quality information on incidence, survival, long term effects and quality of life of survivors as an integral part of childhood cancer surveillance.

It is essential to identify existing evidence on childhood cancer burden, to understand the current scenario and plan for the future. Also, it will highlight the data gaps which need to be addressed when childhood cancer registry is upgraded to a comprehensive registry in Sri Lanka.

## Objectives of generating the publication on 'Childhood Cancer Registry Sri Lanka'

1. To describe the incidence of Childhood cancers in Sri Lanka through the existing evidence of 'National Cancer Registry of Sri Lanka'
2. To describe the incidence & mortality of Childhood cancers in Colombo district through the existing evidence of 'Population Based Cancer Registry of Colombo District'
3. To describe the frequency of newly registered childhood cancer patients at the National Cancer Institute of Sri Lanka through the existing latest evidence of 'Hospital Based Cancer Registry of National Cancer Institute of Sri Lanka'
4. To describe the frequency of newly diagnosed childhood cancer patients at the premier Children Hospitals in Sri Lanka through the existing latest evidence of 'Pathology Laboratory Based Cancer Registry at Lady Ridgeway Hospital for Children, Colombo and Srimavo Bandaranayake Memorial Children Hospital, Peradeniya'
5. To describe the mortality of childhood cancers based on existing evidence of 'Civil Registration System in Sri Lanka'



## Methodology

The routine information systems related to cancer epidemiological measures for incidence, frequency, mortality, survival and type of childhood cancers were revisited. For childhood cancers 0-19 age groups were considered. The relevant data were extracted and reanalyzed. When reanalyzing, childhood cancers were recategorized according to the criteria of International Childhood Cancer Classification- 3rd Revision (ICCC-3). The age specific incidence and mortality rates were calculated for 0-4, 5-9, 10-14 and 15-19 age groups according to the need. Crude, age specific and age standardized incidence and mortality rates were calculated per 1,000,000 population (Generally for adulthood and overall cancer incidence and mortality rates are calculated per 100,000 population).

Following routine information systems were revisited

**1. National Cancer Registry Programme** - The published data were available for 1985 -2019 period.

**2. Population Based Cancer Registry of Colombo district** - The published data were available for 2012-2019 period.

**3. Hospital Based Cancer Registry of National Cancer Institute, Sri Lanka** (Apeksha Hospital, Maharagama)

For hospital based cancer registry of National Cancer Institute, cancer incidence data collected through CanReg 5 software for National Cancer Registry, cancer incidence data collected for the recently commenced Hospital Based Childhood Cancer Registry and Indoor mortality data collected for the Indoor Morbidity & Mortality Return (IMMR) were considered. Newly registered childhood cancer patients in year 2020 and childhood cancer deaths occurred in year 2020 were considered for analysis since it generates most recent available information.




**4. Pathology Laboratory Based Cancer Registries of Lady Ridgeway Hospital for Children, Colombo and Sirimavo Bandaranayake Memorial Children Hospital, Peradeniya** – The relevant data of newly diagnosed cancers at histopathology and haematology laboratories in the year 2020 were considered for analysis since it generates most recent available information.

### **5. Civil Registration System**

All the deaths are registered at the Civil Registration System (Vital Registration) in Sri Lanka. The aggregated data with cause of death data are published by the Registrar General Department through a publication named 'Vital Statistics' and web site of the Department of Census & Statistics of Sri Lanka. Currently cause specific death data and age distribution of deaths are available only up to 2014. Therefore, mortality data 2010-2014 were considered for analysis since it generates most recent available information.



# 1. Incidence of childhood cancers based on National Cancer Registry of Sri Lanka





**Table 1: Distribution of 0-19 year old childhood cancer patients by sex in Sri Lanka 1985-2019**

Year	Male		Female		Total
	No.	%	No.	%	
1985	172	60.8	111	39.2	283
1986	176	61.3	111	38.7	287
1987	196	59.2	135	40.8	331
1990	203	57.8	148	42.2	351
1995	179	52.5	162	47.5	341
2000	259	51.0	249	49.0	508
2005	274	52.4	249	47.6	523
2006	283	51.6	265	48.4	548
2007	293	53.3	257	46.7	550
2008	292	49.6	297	50.4	589
2009	352	56.5	271	43.5	623
2010	347	55.7	276	44.3	623
2011	289	49.4	296	50.6	585
2012	376	54.7	311	45.3	687
2013	341	51.0	328	49.0	669
2014	386	52.2	353	47.8	739
2015	400	49.1	414	50.9	814
2016	475	51.7	443	48.3	918
2017	449	52.1	413	47.9	862
2018	378	49.3	388	50.7	766
2019	402	51.5	378	48.5	780




Figure 1: Number of 0-19 years newly diagnosed childhood cancer patients by sex in Sri Lanka, 2005-2019




Figure 2: Number of newly diagnosed cancer patients 0-19 years and 20 years above in Sri Lanka, 2005 - 2019




Figure 3: Age specific incidence rate of cancers in Sri Lanka - 2019

**Table 2: Crude Incidence Rate per 1,000,000 and Age Standardized Incidence Rate per 1,000,000 among 0-19 year old childhood cancer patients by sex in Sri Lanka 2005 -2019**

Year	Crude Incidence Rate per 1,000,000 population		Age Standardized Incidence Rate per 1,000,000 population	
	Male	Female	Male	Female
2005	75.2	70.9	74.5	71.6
2006	77.8	75.5	77.9	77.2
2007	80	72.4	84.7	73.9
2008	78.9	82.8	81.2	84.5
2009	94.2	74.7	97.3	77.4
2010	92	75.4	97.4	78.4
2011	75.7	79.9	78.4	83.2
2012	110.3	92.4	112.8	93.5
2013	98.9	96.4	100.4	97.1
2014	110.9	102.7	112	103.7
2015	113.8	119.4	114	120.1
2016	133.7	126.3	135.2	125.6
2017	124.9	116.4	127	117
2018	104	108.2	106.6	109
2019	109.9	104.7	111.5	105.1




Figure 4: Crude incidence rate of childhood cancer (0-19 years) in Sri Lanka 2005-2019




Figure 5: Age standardized incidence rate of childhood cancers (0-19 years) in Sri Lanka 2005-2019



**Table 3: Childhood cancer incidence among 0-19 years males by 5 year age groups in Sri Lanka 2015-2019**

Year	0-4		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
2005	63	72.8	60	67.9	64	70.1	87	88.6
2006	76	88.3	51	57.6	68	74.5	88	89.9
2007	118	136.1	58	65	58	63.1	59	59.8
2008	96	109.6	64	71	49	52.8	83	83.2
2009	113	128	85	93.1	67	71.7	87	86.6
2010	142	159.2	68	73.8	51	54.1	86	84.7
2011	98	108.4	66	71	47	49.1	78	75.9
2012	136	154.7	84	95.2	72	86.8	84	102.4
2013	115	129.3	55	61.7	69	82.3	102	123
2014	117	130.3	97	107.7	76	89.8	96	114.7
2015	107	118.1	90	99.0	85	99.5	118	139.7
2016	150	163.7	92	100.1	86	99.5	147	172.1
2017	153	165.0	80	86.0	94	107.6	122	141.2
2018	141	150.4	72	76.6	75	84.9	90	103.0
2019	131	138.9	86	90.9	80	90.0	105	119.5

**Table 4 : Childhood cancer incidence among 0-19 years females by 5 year age groups in Sri Lanka 2015-2019**

Year	00-04		05-09		10-14		15-19	
	No.	Ag.Sp.Rate	No.	Ag.Sp.Rate	No.	Ag.Sp.Rate	No.	Ag.Sp.Rate
2005	70	83.7	50	57.7	59	67.4	70	74.9
2006	84	101.4	51	59.6	55	62.7	75	78.8
2007	82	98	49	56.7	46	51.9	80	83.1
2008	97	114.7	52	59.6	51	56.9	97	99.7
2009	94	109.9	57	64.3	42	46.3	78	79.7
2010	94	108.9	71	79.3	32	34.9	79	80
2011	110	126	49	54.4	59	63.8	78	77.7
2012	99	114.5	65	75.1	56	69.1	91	110.4
2013	102	116.6	56	64	61	74.4	109	130.8
2014	113	128	51	57.7	67	80.9	122	145
2015	124	139.1	78	87.4	70	83.8	142	167.2
2016	111	123.1	81	89.8	101	119.5	150	174.6
2017	126	138.2	55	60.3	87	101.8	145	166.9
2018	121	131.3	62	67.2	68	78.7	137	156.0
2019	112	120.7	64	68.9	66	75.9	136	153.9




Figure 6: Age specific incidence rate per 1,000,000 among 00-04 year old childhood cancer patients by sex in Sri Lanka 2005 -2019




Figure 7 : Age specific incidence rate per 1,000,000 among 05-09 year old childhood cancer patients by sex in Sri Lanka 2005 -2019




Figure 8 : Age specific incidence rate per 1,000,000 among 10-14year old childhood cancer patients by sex in Sri Lanka 2005 -2019




Figure 9: Age specific incidence rate per 1,000,000 among 15-19 year old childhood cancer patients by sex in Sri Lanka 2005 -2019

**Table 5: Childhood cancer incidence among 0-19 years males by 5 year age group in Sri Lanka 2015 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases, and myelodysplastic diseases	41	45.2	32	35.2	34	39.8	20	23.7
II Lymphomas and reticuloendothelial neoplasms	10	11.0	13	14.3	10	11.7	24	28.4
III CNS and miscellaneous intracranial and intraspinal neoplasms	7	7.7	9	9.9	5	5.9	10	11.8
IV Neuroblastoma and other peripheral nervous cell tumours	15	16.6	5	5.5	1	1.2	0	0.0
V Retinoblastoma	7	7.7	2	2.2	1	1.2	0	0.0
VI Renal tumours	11	12.1	2	2.2	1	1.2	1	1.2
VII Hepatic tumours	6	6.6	4	4.4	2	2.3	0	0.0
VIII Malignant bone tumours	1	1.1	6	6.6	10	11.7	32	37.9
IX Soft tissue and other extraosseous sarcoma	4	4.4	6	6.6	6	7.0	11	13.0
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	4	4.4	5	5.5	2	2.3	4	4.7
XI Other malignant epithelial neoplasms and malignant melanomas	0	0.0	3	3.3	10	11.7	12	14.2
XII Other and unspecified malignant neoplasms	1	1.1	3	3.3	3	3.5	4	4.7
<b>Total</b>	<b>107</b>	<b>118.1</b>	<b>90</b>	<b>99.0</b>	<b>85</b>	<b>99.5</b>	<b>118</b>	<b>139.7</b>

**Table 6: Childhood cancer incidence among 0-19 years females by 5 year age group in Sri Lanka 2015 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases, and myelodysplastic diseases	33	37.0	19	21.3	18	21.5	19	22.4
II Lymphomas and reticuloendothelial neoplasms	10	11.2	6	6.7	8	9.6	20	23.5
III CNS and miscellaneous intracranial and intraspinal neoplasms	5	5.6	15	16.8	4	4.8	11	13.0
IV Neuroblastoma and other peripheral nervous cell tumours	7	7.9	6	6.7	0	0	0	0.0
V Retinoblastoma	22	24.7	5	5.6	0	0	0	0.0
VI Renal tumours	13	14.6	3	3.4	0	0	0	0.0
VII Hepatic tumours	2	2.2	0	0	0	0	1	1.2
VIII Malignant bone tumours	1	1.1	6	6.7	16	19.1	17	20.0
IX Soft tissue and other extraosseous sarcoma	11	12.3	6	6.7	3	3.6	8	9.4
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	9	10.1	9	10.1	12	14.4	8	9.4
XI Other malignant epithelial neoplasms and malignant melanomas	6	6.7	2	2.2	8	9.6	52	61.2
XII Other and unspecified malignant neoplasms	5	5.6	1	1.1	1	1.2	6	7.1
<b>Total</b>	<b>124</b>	<b>139.1</b>	<b>78</b>	<b>87.4</b>	<b>70</b>	<b>83.8</b>	<b>142</b>	<b>167.2</b>

**Table 7: Childhood cancer incidence among 0-19 years males by 5 year age group in Sri Lanka 2016 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases, and myelodysplastic diseases	59	64.4	39	42.4	23	26.6	36	42.1
II Lymphomas and reticuloendothelial neoplasms	8	8.7	9	9.8	12	13.9	30	35.1
III CNS and miscellaneous intracranial and intraspinal neoplasms	9	9.8	12	13.1	12	13.9	13	15.2
IV Neuroblastoma and other peripheral nervous cell tumours	14	15.3	3	3.3	0	0.0	1	1.2
V Retinoblastoma	19	20.7	2	2.2	0	0.0	0	0.0
VI Renal tumours	11	12.0	3	3.3	2	2.3	2	2.3
VII Hepatic tumours	2	2.2	3	3.3	1	1.2	2	2.3
VIII Malignant bone tumours	6	6.5	9	9.8	14	16.2	23	26.9
IX Soft tissue and other extraosseous sarcoma	8	8.7	5	5.4	7	8.1	6	7.0
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	4	4.4	4	4.4	4	4.6	12	14.0
XI Other malignant epithelial neoplasms and malignant melanomas	5	5.5	2	2.2	7	8.1	18	21.1
XII Other and unspecified malignant neoplasms	5	5.5	1	1.1	4	4.6	4	4.7
<b>Total</b>	<b>150</b>	<b>163.7</b>	<b>92</b>	<b>100.1</b>	<b>86</b>	<b>99.5</b>	<b>147</b>	<b>172.1</b>

**Table 8: Childhood cancer incidence among 0-19 years females by 5 year age group in Sri Lanka 2016 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases, and myelodysplastic diseases	37	41.0	19	21.1	20	23.7	15	17.5
II Lymphomas and reticuloendothelial neoplasms	1	1.1	6	6.7	8	9.5	16	18.6
III CNS and miscellaneous intracranial and intraspinal neoplasms	4	4.4	16	17.7	10	11.8	7	8.1
IV Neuroblastoma and other peripheral nervous cell tumours	8	8.9	7	7.8	2	2.4	0	0.0
V Retinoblastoma	13	14.4	7	7.8	0	0.0	0	0.0
VI Renal tumours	5	5.5	1	1.1	1	1.2	0	0.0
VII Hepatic tumours	5	5.5	0	0.0	0	0.0	1	1.2
VIII Malignant bone tumours	3	3.3	7	7.8	18	21.3	15	17.5
IX Soft tissue and other extraosseous sarcoma	13	14.4	9	10.0	5	5.9	8	9.3
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	7	7.8	3	3.3	14	16.6	23	26.8
XI Other malignant epithelial neoplasms and malignant melanomas	11	12.2	2	2.2	20	23.7	62	72.2
XII Other and unspecified malignant neoplasms	4	4.4	4	4.4	3	3.5	3	3.5
<b>Total</b>	<b>111</b>	<b>123.1</b>	<b>81</b>	<b>89.8</b>	<b>101</b>	<b>119.5</b>	<b>150</b>	<b>174.6</b>



**Table 9: Childhood cancer incidence among 0-19 years males by 5 year age group in Sri Lanka 2017 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases	52	56.1	25	26.9	31	35.5	25	28.9
II Lymphomas and reticuloendothelial neoplasms	7	7.5	11	11.8	14	16.0	18	20.8
III CNS and miscellaneous intracranial and intraspinal neoplasms	9	9.7	14	15.1	6	6.9	6	6.9
IV Neuroblastoma and other peripheral nervous cell tumours	11	11.9	7	7.5	0	0	0	0.0
V Retinoblastoma	15	16.2	0	0.0	0	0	0	0.0
VI Renal tumours	12	12.9	2	2.2	1	1.1	0	0.0
VII Hepatic tumours	8	8.6	2	2.2	0	0	3	3.5
VIII Malignant bone tumours	1	1.1	6	6.5	10	11.4	29	33.6
IX Soft tissue and other extraosseous sarcoma	20	21.6	3	3.2	14	16.0	10	11.6
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	7	7.5	1	1.1	5	5.7	6	6.9
XI Other malignant epithelial neoplasms and malignant melanomas	2	2.2	4	4.3	10	11.4	19	22.0
XII Other and unspecified malignant neoplasms	9	9.7	5	5.4	3	3.4	6	6.9
<b>Total</b>	<b>153</b>	<b>165.0</b>	<b>80</b>	<b>86.0</b>	<b>94</b>	<b>107.6</b>	<b>122</b>	<b>141.2</b>

Table 10: Childhood cancer incidence among 0-19 years females by 5 year age group in Sri Lanka 2017 according to ICCC-3

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases	41	45.0	12	13.1	18	21.1	12	13.8
II Lymphomas and reticuloendothelial neoplasms	4	4.4	6	6.6	7	8.2	18	20.7
III CNS and miscellaneous intracranial and intraspinal neoplasms	7	7.7	9	9.9	7	8.2	2	2.3
IV Neuroblastoma and other peripheral nervous cell tumours	12	13.2	4	4.4	1	1.2	1	1.2
V Retinoblastoma	16	17.5	3	3.3	0	0	0	0
VI Renal tumours	16	17.5	3	3.3	0	0	1	1.2
VII Hepatic tumours	4	4.4	1	1.1	1	1.2	0	0
VIII Malignant bone tumours	1	1.1	4	4.4	21	24.6	8	9.2
IX Soft tissue and other extraosseous sarcoma	9	9.9	2	2.2	10	11.7	7	8.1
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	4	4.4	6	6.6	6	7.0	38	43.7
XI Other malignant epithelial neoplasms and malignant melanomas	6	6.6	3	3.3	13	15.2	53	61.0
XII Other and unspecified malignant neoplasms	6	6.6	2	2.2	3	3.5	5	5.8
<b>Total</b>	<b>126</b>	<b>138.2</b>	<b>55</b>	<b>60.3</b>	<b>87</b>	<b>101.8</b>	<b>145</b>	<b>166.9</b>

**Table 11: Childhood cancer incidence among 0-19 years males by 5 year age group in Sri Lanka 2018 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases	39	41.6	22	23.4	17	19.2	9	10.3
II Lymphomas and reticuloendothelial neoplasms	5	5.3	10	10.6	14	15.8	22	25.2
III CNS and miscellaneous intracranial and intraspinal neoplasms	6	6.4	8	8.5	8	9.1	4	4.6
IV Neuroblastoma and other peripheral nervous cell tumours	11	11.7	6	6.4	0	0	0	0
V Retinoblastoma	27	28.8	8	8.5	1	1.1	1	1.1
VI Renal tumours	11	11.7	3	3.2	0	0	1	1.1
VII Hepatic tumours	11	11.7	2	2.1	1	1.1	1	1.1
VIII Malignant bone tumours	1	1.1	2	2.1	10	11.3	14	16.0
IX Soft tissue and other extraosseous sarcoma	9	9.6	7	7.4	9	10.2	3	3.4
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	6	6.4	0	0	0	0	7	8.0
XI Other malignant epithelial neoplasms and malignant melanomas	10	10.7	4	4.3	10	11.3	18	20.6
XII Other and unspecified malignant neoplasms	5	5.3	0	0	5	5.7	10	11.4
<b>Total</b>	<b>141</b>	<b>150.4</b>	<b>72</b>	<b>76.6</b>	<b>75</b>	<b>84.9</b>	<b>90</b>	<b>103.0</b>

**Table 12: Childhood cancer incidence among 0-19 years females by 5 year age group in Sri Lanka 2018 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukemias, myeloproliferative diseases and myelodysplastic diseases	29	31.5	16	17.3	13	15.0	13	14.8
II Lymphomas and reticuloendothelial neoplasms	2	2.2	5	5.4	8	9.3	19	21.6
III CNS and miscellaneous intracranial and intraspinal neoplasms	5	5.4	6	6.5	5	5.8	6	6.8
IV Neuroblastoma and other peripheral nervous cell tumours	9	9.8	1	1.1	0	0	0	0
V Retinoblastoma	23	25.0	9	9.8	2	2.3	0	0
VI Renal tumours	12	13.0	5	5.4	1	1.2	0	0.0
VII Hepatic tumours	3	3.3	0	0	0	0	1	1.1
VIII Malignant bone tumours	3	3.3	3	3.3	8	9.3	11	12.5
IX Soft tissue and other extraosseous sarcoma	27	29.3	7	7.6	3	3.5	6	6.8
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	4	4.3	3	3.3	12	13.9	12	13.7
XI Other malignant epithelial neoplasms and malignant melanomas	3	3.3	3	3.3	14	16.2	63	71.7
XII Other and unspecified malignant neoplasms	1	1.1	4	4.3	2	2.3	6	6.8
<b>Total</b>	<b>121</b>	<b>131.3</b>	<b>62</b>	<b>67.2</b>	<b>68</b>	<b>78.7</b>	<b>137</b>	<b>156.0</b>

**Table 13: Childhood cancer incidence among 0-19 years males by 5 year age group in Sri Lanka 2019 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases	34	36.0	24	25.4	13	14.6	18	20.5
II Lymphomas and reticuloendothelial neoplasms	4	4.2	11	11.6	17	19.1	13	14.8
III CNS and miscellaneous intracranial and intraspinal neoplasms	13	13.8	23	24.3	10	11.2	7	8.0
IV Neuroblastoma and other peripheral nervous cell tumours	9	9.5	3	3.2	3	3.4	0	0
V Retinoblastoma	10	10.6	2	2.1	0	0	0	0
VI Renal tumours	18	19.1	4	4.2	0	0	0	0
VII Hepatic tumours	6	6.4	0	0	2	2.2	0	0
VII I Malignant bone tumours	0	0	1	1.1	15	16.9	17	19.3
IX Soft tissue and other extraosseous sarcoma	18	19.1	10	10.6	8	9.0	7	8.0
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	6	6.4	1	1.1	0	0	8	9.1
XI Other malignant epithelial neoplasms and malignant melanomas	3	3.2	4	4.2	8	9.0	29	33.0
XII Other and unspecified malignant neoplasms	10	10.6	3	3.2	4	4.5	6	6.8
<b>Total</b>	<b>131</b>	<b>138.9</b>	<b>86</b>	<b>90.9</b>	<b>80</b>	<b>90.0</b>	<b>105</b>	<b>119.5</b>

**Table 14: Childhood cancer incidence among 0-19 years females by 5 year age group in Sri Lanka 2019 according to ICCC-3**

No and ICCC-3	00-04		05-09		10-14		15-19	
	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate	No.	Ag.Sp. Rate
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases	35	37.7	23	24.8	16	18.4	9	10.2
II Lymphomas and reticuloendothelial neoplasms	4	4.3	5	5.4	4	4.6	13	14.7
III CNS and miscellaneous intracranial and intraspinal neoplasms	8	8.6	12	12.9	6	6.9	3	3.4
IV Neuroblastoma and other peripheral nervous cell tumours	12	12.9	2	2.2	0	0.0	2	2.3
V Retinoblastoma	13	14.0	4	4.3	0	0.0	0	0.0
VI Renal tumours	7	7.5	3	3.2	0	0.0	0	0.0
VII Hepatic tumours	4	4.3	1	1.1	0	0.0	0	0.0
VIII Malignant bone tumours	2	2.2	3	3.2	12	13.8	7	7.9
IX Soft tissue and other extraosseous sarcoma	14	15.1	3	3.2	9	10.3	12	13.6
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	2	2.2	1	1.1	5	5.7	18	20.4
XI Other malignant epithelial neoplasms and malignant melanomas	6	6.5	2	2.2	11	12.6	68	76.9
XII Other and unspecified malignant neoplasms	5	5.4	5	5.4	3	3.4	4	4.5
<b>Total</b>	<b>112</b>	<b>120.7</b>	<b>64</b>	<b>68.9</b>	<b>66</b>	<b>75.9</b>	<b>136</b>	<b>153.9</b>

**Table 15: Distribution of WHO GICC index cancers**

**Acute Lymphoblastic Leukaemia**

Year	Male			Female		
	No.	CR	ASR	No.	CR	ASR
2015	100	28.5	28.9	57	16.4	17
2016	112	31.5	32.8	69	19.7	20.4
2017	107	29.8	30.6	65	18.3	19.4
2018	38	10.5	11.6	32	8.9	9.3
2019	26	7.1	7.1	21	5.8	6.2

**Hodgkin's Lymphoma**

Year	Male			Female		
	No.	CR	ASR	No.	CR	ASR
2015	21	6	5.7	12	3.5	3.2
2016	24	6.8	6.3	20	5.7	5.3
2017	19	5.3	5.1	20	5.6	5.2
2018	22	6.1	5.7	10	2.8	2.6
2019	11	3	2.8	13	3.6	3.4

**Burkitt lymphoma**

Year	Male			Female		
	No.	CR	ASR	No.	CR	ASR
2015	2	0.6	0.5	0	0	0
2016	3	0.8	0.9	0	0	0
2017	3	0.8	0.8	2	0.6	0.6
2018	2	0.6	0.5	0	0	0
2019	5	1.4	1.3	0	0	0

## Wilm's Tumour

Year	Male			Female		
	No.	CR	ASR	No.	CR	ASR
2015	14	4	4.5	15	4.3	4.9
2016	17	4.9	5.2	5	1.4	1.6
2017	15	4.2	4.7	18	5.1	5.8
2018	14	3.9	4.3	18	5	5.5
2019	20	5.5	6.2	10	2.8	3.1

## Retinoblastoma


Year	Male			Female		
	No.	CR	ASR	No.	CR	ASR
2015	10	2.8	3.1	27	7.8	8.8
2016	20	5.6	6.4	20	5.7	6.3
2017	15	4.2	4.9	19	5.4	6.1
2018	37	10.2	11.3	34	9.45	10.5
2019	12	3.3	3.7	17	4.7	5.3

## Low grade glioma


Year	Male			Female		
	No.	CR	ASR	No.	CR	ASR
2015	3	0.9	0.9	8	2.3	2.2
2016	19	5.4	5.1	4	2.9	2.7
2017	7	1.9	2.1	5	1.4	1.5
2018	6	1.7	1.7	6	1.7	1.6
2019	12	3.3	3.3	5	1.4	1.4



**Leading childhood cancers (00-19 years) of Sri Lanka according to age group**



**Figure 10: Leading cancers by 00 - 04 year age group among males in Sri Lanka 2015-2019**



**Figure 11: Leading cancers by 00 - 04 year age group among females in Sri Lanka 2015-2019**




Figure 12: Leading cancers by 05 - 09 year age group among males in Sri Lanka 2015-2019




Figure 13: Leading cancers by 05 - 09 year age group among females in Sri Lanka 2015-2019




Figure 14: Leading cancers by 10-14 year age group among males in Sri Lanka 2015-2019




Figure 15: Leading cancers by 10-14 year age group among females in Sri Lanka 2015-2019




Figure 16: Leading cancers by 15-19 year age group among males in Sri Lanka 2015-2019




Figure 17: Leading cancers by 15-19 year age group among females in Sri Lanka 2015-2019

Table 16 : Distribution of childhood cancers among 0-19 years in 2015 – 2019 according to district

Province	District	2015	2016	2017	2018	2019
<b>Western</b>						
	Colombo	95	89	122	85	133
	Gampaha	59	84	60	52	51
	Kalutara	31	25	49	39	28
<b>Central</b>						
	Kandy	46	58	50	65	50
	Matale	14	19	11	12	13
	Nuwara Eliya	18	14	23	22	22
<b>Southern</b>						
	Galle	30	31	38	25	35
	Hambantota	18	13	16	26	11
	Matara	28	25	21	12	9
<b>Northern</b>						
	Jaffna	28	24	15	13	20
	Kilinochchi	2	2	3	6	4
	Mannar	2	2	5	3	2
	Mullaitivu	3	8	9	1	4
	Vavuniya	4	8	3	2	2
<b>Eastern</b>						
	Ampara	21	26	20	12	16
	Batticaloa	27	24	9	10	15
	Trincomalee	11	15	15	10	7
<b>North Western</b>						
	Kurunegala	41	60	41	45	44
	Puttalam	16	30	23	25	26
<b>North Central</b>						
	Anuradhapura	27	26	29	25	18
	Polonnaruwa	16	10	12	10	14
<b>Uva</b>						
	Badulla	19	41	30	19	13
	Moneragala	13	22	12	12	20
<b>Sabaragamuwa</b>						
	Kegalle	18	23	18	17	26
	Ratnapura	38	44	24	37	28
<b>District not known</b>		<b>189</b>	<b>195</b>	<b>204</b>	<b>181</b>	<b>169</b>
<b>Total</b>		<b>814</b>	<b>918</b>	<b>862</b>	<b>766</b>	<b>780</b>

**Table 17 : Childhood cancer incidence data (0-19) Male, Sri Lanka 2015 - 2019**

Site Group		ICD -O-3 Histology			Male				
				2015	2016	2017	2018	2019	
<b>I</b>	<b>Leukaemias, myeloproliferative diseases, and myelodysplastic diseases</b>								
	a. Lymphoid leukaemia	9811	B lymphoblastic leukaemia/lymphoma, NOS	0	2	0	0	0	
		9820	Lymphoid leukaemia	0	0	2	15	1	
		9823	B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma	0	0	1	0	0	
		9826	Burkitt cell leukaemia	0	2	2	0	2	
		9833	Prolymphocytic leukaemia-cell type	0	0	0	1	0	
		9835	Precursor cell lymphoblastic leukaemia, NOS	54	98	99	5	12	
		9836	Precursor B-cell lymphoblastic leukaemia	32	9	1	12	8	
		9837	Precursor T-cell lymphoblastic leukaemia	14	1	2	3	3	
		9940	Hairy cell leukaemia	0	0	0	1	0	
	b. Acute myeloid leukaemia	9840	Acute myeloid leukaemia, M6 type	0	0	1	0	0	
		9861	Acute myeloid leukaemia, NOS	11	22	13	10	9	
		9866	Acute promyelocytic leukaemia, t(15;17)(q22;q11-	1	0	2	0	1	
		9867	Acute myelomonocytic leukaemia	1	0	1	1	0	
		9874	Acute myeloid leukaemia with maturation	2	5	3	0	0	
		9891	Acute monocytic leukaemia	3	0	1	0	0	
		9910	Acute megakaryoblastic leukaemia	2	2	0	0	0	
	c. Chronic myeloproliferative diseases	9863	Chronic myeloid leukaemia, NOS	3	4	1	3	2	
		9875	Chronic myeloid leukaemia BCR/ABL positive	0	1	0	1	0	
	d. Myelodysplastic syndrome and other myeloproliferative diseases	9946	Juvenile myelomonocytic leukaemia	1	1	0	0	0	
		9983	Refractory anaemia with excess blasts	0	1	0	0	0	
		9989	Myelodysplastic syndrome, NOS	1	1	2	0	0	

Site Group	ICD -O-3 Histology	Male					
		2015	2016	2017	2018	2019	
e. Unspecified and other specified leukaemia	9800	Leukaemia NOS	0	1	2	1	1
	9801	Acute leukaemia, NOS	2	7	0	0	50
	9860	Myeloid leukaemia NOS	0	0	0	34	0
	9930	Myeloid sarcoma	0	1	0	0	0
<b>Total</b>			<b>127</b>	<b>157</b>	<b>133</b>	<b>87</b>	<b>89</b>

## II Lymphomas and reticuloendothelial neoplasms

a. Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	19	16	9	12	9
	9651	Hodgkin lymphoma, lymphocyte-rich	1	0	1	1	0
	9652	Hodgkin lymphoma, mixed cellularity, NOS	0	3	5	4	1
	9659	Hodgkin lymphoma, nodular lymphocyte predominance	0	0	1	0	1
	9663	Hodgkin lymphoma, nodular sclerosis, NOS	1	5	2	4	0
	9664	Hodgkin lymphoma, nodular sclerosis, cellular phase	0	0	1	0	0
	9667	Hodgkin lymphoma, nodular sclerosis, grade 2	0	0	0	1	0
b. Non_Hodgkin lymphomas (except Burkitt lymphoma)	9590	Malignant lymphoma, NOS	0	0	0	0	3
	9591	Malignant lymphoma, non-Hodgkin, NOS	13	19	10	10	9
	9670		0	0	0	1	0
	9680	Malignant lymphoma, large B-cell, diffuse, NOS	2	1	1	0	1
	9690	Follicular lymphoma, NOS	1	0	0	0	0
	9695	Follicular lymphoma, grade 1	0	1	0	0	0
	9699	Marginal zone B-cell lymphoma, NOS	0	0	1	0	0
	9700	Mycosis fungoides	1	2	2	3	1
	9702	Mature T-cell lymphoma, NOS	1	0	1	0	1
	9709	Cutaneous T-cell lymphoma, NOS	0	0	1	0	0
	9714	Anaplastic large cell lymphoma, T cell and	3	0	2	0	1
	9727	Precursor cell lymphoblastic lymphoma, NOS	1	2	1	0	0
	9728	Precursor B-cell lymphoblastic lymphoma	0	0	0	0	2
	9729	Precursor T-cell lymphoblastic lymphoma	2	1	0	5	5
	9732	Multiple myeloma	1	0	0	1	0
c. Burkitt lymphoma	9687	Burkitt lymphoma, NOS	2	3	3	2	5

Site Group	ICD -O-3 Histology	Male					
		2015	2016	2017	2018	2019	
d. Miscellaneous lymphoreticular neoplasms	9750	Malignant lymphoma, NOS	0	0	0	0	2
	9751	Langerhans cell histiocytosis, NOS	0	0	3	0	0
	9754	Langerhans cell histiocytosis, disseminated	4	2	0	2	0
	9755	Histiocytic sarcoma	1	0	0	0	0
e. Unspecified lymphomas	9590	Malignant lymphoma, NOS	4	4	6	5	4
<b>Total</b>			<b>57</b>	<b>59</b>	<b>50</b>	<b>51</b>	<b>45</b>

### III CNS and miscellaneous intracranial and intraspinal neoplasms

a. Ependymomas and choroid plexus tumour	9390	Choroid plexus carcinoma	1	2	0	0	0
	9391	Ependymoma, NOS	1	2	4	1	4
	9392	Ependymoma, anaplastic	1	1	3	1	5
b. Astrocytoma	9380	Glioma, malignant	1	1	0	1	0
	9400	Astrocytoma, NOS	2	13	2	5	7
	9401	Astrocytoma, anaplastic	0	0	0	2	1
	9420	Fibrillary astrocytoma	1	0	0	0	1
	9424	Pleomorphic xanthoastrocytoma	0	1	1	0	1
	9425	Pilomyxoid astrocytoma	0	1	0	0	0
	9430	Astroblastoma	0	0	0	0	1
	9440	Glioblastoma, NOS	2	0	1	0	2
c. Intracranial and intraspinal embryonal tumours	9470	Medulloblastoma, NOS	10	10	11	5	10
	9471	Desmoplastic nodular medulloblastoma	0	1	1	1	0
	9473	Primitive neuroectodermal tumour, NOS	1	2	0	1	0
	9508	Atypical teratoid/Rhabdoid tumour	0	0	0	1	0
d. Other gliomas	9380	Glioma, malignant	9	7	7	6	13
	9382	Mixed glioma	0	1	0	0	0
	9450	Oligodendroglioma, NOS	0	1	0	0	1
	9451	Oligodendroglioma, anaplastic	1	2	1	0	1
f. Unspecified intracranial and intraspinal neoplasms	8000	Neoplasm, malignant	1	1	4	2	6



Site Group		ICD -O-3 Histology			Male				
				2015	2016	2017	2018	2019	
<b>Total</b>				<b>31</b>	<b>46</b>	<b>35</b>	<b>26</b>	<b>53</b>	
<b>IV Neuroblastoma and other peripheral nervous cell tumours</b>									
a. Neuroblastoma and ganglioneuroblastom	9490	Ganglioneuroblastoma		5	5	6	2	2	
	9500	Neuroblastoma, NOS		15	14	11	15	12	
b. Other peripheral nervous cell tumour	9520	Olfactory neurogenic tumour		1	0	0	0	0	
	8680	Paraganglioma, malignant		0	0	0	0	1	
	8700	Pheochromocytoma, malignant		0	0	1	0	0	
<b>Total</b>				<b>21</b>	<b>19</b>	<b>18</b>	<b>17</b>	<b>15</b>	
<b>V Retinoblastoma</b>									
Retinoblastoma	9510	Retinoblastoma, NOS		9	20	15	38	12	
	9511	Retinoblastoma, differentiated		1	0	0	0	0	
<b>Total</b>				<b>10</b>	<b>20</b>	<b>15</b>	<b>38</b>	<b>12</b>	
<b>VI Renal tumours</b>									
a. Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS		14	17	13	12	16	
	8964	Clear cell sarcoma of kidney		0	0	2	2	4	
B. Renal carcinomas	8120	Transitional cell carcinoma		0	0	0	1	0	
	8312	Renal cell carcinoma, NOS		0	1	0	0	1	
c. Unspecified malignant renal tumours	8000	Neoplasm, malignant		1	0	0	0	1	
<b>Total</b>				<b>15</b>	<b>18</b>	<b>15</b>	<b>15</b>	<b>22</b>	
<b>VII Hepatic tumours</b>									
a. Hepatoblastoma	8970	Hepatoblastoma		9	4	10	13	6	
b. Hepatic carcinomas	8170	Hepatocellular carcinoma, NOS		2	4	2	2	2	
c. Unspecified hepatic tumours	8000	Neoplasm, malignant		1	0	1	0	0	
<b>Total</b>				<b>12</b>	<b>8</b>	<b>13</b>	<b>15</b>	<b>8</b>	
<b>VIII Malignant bone tumours</b>									
a. Osteosarcoma	9180	Osteosarcoma, NOS		31	27	23	12	18	
	9181	Chondroblastic osteosarcoma		4	1	2	5	3	
	9186	Central Osteosarcoma		0	1	3	1	1	
b. Chondrosarcomas	9220	Chondrosarcoma, NOS		0	1	2	1	0	

Site Group	ICD -O-3 Histology	Male				
		2015	2016	2017	2018	2019
c. Ewing tumours and related sarcomas of bone	9260 Ewing sarcoma	11	15	12	6	7
d. Other specified malignant bone tumours	9250 Giant cell tumour of bone, malignant	1	2	0	0	1
	9261 Adamantinoma of long bones	0	0	0	1	0
	9270 Odontogenic tumour, malignant	0	0	0	1	0
	9330 Ameloblastic fibrosarcoma	1	1	0	0	0
	9370 Chordoma	0	1	0	0	0
e. Unspecified malignant bone tumours	8000 Neoplasm, malignant	1	0	3	0	0
	8800 Sarcoma, NOS	0	2	1	0	0
	8801 Spindle cell sarcoma	0	1	0	0	0
<b>Total</b>		<b>49</b>	<b>52</b>	<b>46</b>	<b>27</b>	<b>30</b>

#### IX Soft tissue and other extrasosseous sarcoma

a. Rhabdomyosarcoma	8900 Rhabdomyosarcoma, NOS	7	6	7	5	10
	8902 Mixed type rhabdomyosarcoma	0	0	0	0	1
	8910 Embryonal rhabdomyosarcoma, NOS	4	2	0	3	3
	8912 Spindle cell rhabdomyosarcoma	0	0	1	0	0
	8920 Alveolar rhabdomyosarcoma	2	1	1	0	0
b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms	8813 Fascial fibrosarcoma	0	0	0	0	1
	9540 Malignant peripheral nerve sheath tumour	1	0	0	0	0
	9560 Neurilemoma, malignant	0	1	0	0	0
	9580 Granular cell tumour, malignant	0	0	1	0	1
d. Other specified soft tissue sarcomas	8806 Desmoplastic small round cell tumour	3	5	19	12	13
	8832 Dermatofibrosarcoma, NOS	2	0	1	0	2
	8858 Dedifferentiated liposarcoma	0	0	0	1	0
	8870 Myelolipoma	0	0	0	1	0
	8890 Leiomyosarcoma, NOS	1	0	0	0	0
	8894 Angiomyosarcoma	1	0	0	0	0
	8921 Rhabdomyosarcoma with ganglionic differentiation	0	1	0	0	0

Site Group		ICD -O-3 Histology			Male				
				2015	2016	2017	2018	2019	
		8963	Malignant rhabdoid tumour	0	1	0	0	0	
		9040	Synovial sarcoma, NOS	2	3	3	1	0	
		9041	Synovial sarcoma, spindle cell	2	1	1	0	0	
		9043	Synovial sarcoma, biphasic	0	0	1	0	0	
		9133	Epithelioid hemangioendothelioma, malignant	0	0	0	1	0	
		9260	Ewing sarcoma	1	1	3	2	9	
		9581	Alveolar soft part sarcoma	0	1	1	0	0	
	e. Unspecified soft tissue sarcomas	8800	Sarcoma, NOS	1	3	8	3	3	
<b>Total</b>				<b>27</b>	<b>26</b>	<b>47</b>	<b>29</b>	<b>43</b>	
<b>X</b>	<b>Germ cell tumours, trophoblastic tumours, and neoplasms of gonads</b>								
	a. Intracranial and intraspinal germ cell tumours	9064	Germinoma	1	5	2	0	0	
		9070	Embryonal carcinoma, NOS	1	0	3	0	1	
		9080	Teratoma, malignant NOS	0	0	0	1	0	
		9085	Mixed germ cell tumour	0	0	1	0	0	
	b. Malignant extracranial and extragonadal germ cell tumours	9064	Germinoma	1	5	1	2	2	
		9065	Germ cell tumour, nonseminomatous	0	0	0	1	0	
		9070	Embryonal carcinoma, NOS	1	0	1	0	1	
		9071	Yolk sac tumour	3	0	1	1	2	
		9080	Teratoma, malignant, NOS	4	3	0	0	1	
		9085	Mixed germ cell tumour	1	1	2	2	0	
	c. Malignant gonadal germ cell tumours	9061	Seminoma, NOS	0	1	0	0	0	
		9064	Germinoma	1	1	2	1	0	
		9065	Germ cell tumour, nonseminomatous	0	1	1	0	0	
		9070	Embryonal carcinoma, NOS	1	0	0	0	0	
		9071	Yolk sac tumour	0	4	2	1	0	
		9080	Teratoma, malignant, NOS	1	0	1	0	5	
		9082	Malignant teratoma, undifferentiated	0	0	0	1	0	

Site Group	ICD -O-3 Histology	Male					
		2015	2016	2017	2018	2019	
	9085	Mixed germ cell tumour	0	3	1	1	1
	8000	Neoplasm,malignant	0	0	1	2	1
e. Other and unspecified malignant gonadal tumours	8631	Sertoli-Leydig cell tumour, poorly differentiate	0	0	0	0	1
<b>Total</b>			<b>15</b>	<b>24</b>	<b>19</b>	<b>13</b>	<b>15</b>

## XI Other malignant epithelial neoplasms and malignant melanomas

a. Adrenocortical carcinoma	8370	Adrenal cortical carcinoma	0	0	0	3	0
b. Thyroid carcinomas	8050	Papillary carcinoma,NOS	0	2	0	1	0
	8260	Papillary adenocarcinoma, NOS	8	4	9	7	8
	8290	Oxyphillic adenocarcinoma	0	1	0	0	0
	8330	Follicular adenocarcinoma, NOS	0	3	1	2	2
	8331	Follicular adenocarcinoma, well differentiated	0	0	0	1	0
	8335	Follicular carcinoma, minimally invasive	0	0	1	0	1
	8340	Papillary carcinoma, follicular variant	0	0	0	1	1
	8341	Papillary microcarcinoma	0	1	0	2	1
	8346	Mixed medullary-follicular carcinoma	0	0	0	0	1
	8510	Medullary carcinoma, NOS	1	0	0	0	0
c. Nasopharyngeal carcinomas	8010	Carcinoma,NOS	0	2	0	1	0
	8070	Squamous cell carcinoma, NOS	1	1	1	0	1
	8072	Squamous cell carcinoma, NOS	0	1	1	0	1
d. Malignant melanomas	8720	Malignant melanoma, NOS (except juvenile melanoma)	0	0	0	1	1
e. Skin carcinomas	8031	Giant cell carcinoma	0	0	0	0	0
	8032	Spindle cell carcinoma,NOS	0	1	0	0	0
	8090	Basal cell carcinoma, NOS	0	0	0	1	0
	8070	Squamous cell carcinoma, NOS	0	0	2	0	2
	8320	Granular cell carcinoma	0	0	0	0	0
	8390	Skin appendage carcinoma	0	0	1	0	0
f. Other and unspecified carcinomas	8010	Carcinoma, NOS	2	0	0	5	3
	8050	Papillary Carcinoma, NOS	0	0	0	1	0

Site Group		ICD -O-3 Histology			Male				
				2015	2016	2017	2018	2019	
	8051	Verrucous carcinoma, NOS		0	0	0	1	0	
	8070	Squamous cell carcinoma, NOS		1	6	1	3	6	
	8120	Transitional cell carcinoma, NOS		0	0	2	1	0	
	8130	Papillary transitional cell carcinoma		1	1	1	0	0	
	8140	Adenocarcinoma, NOS		4	2	4	4	4	
	8200	Adenoid cystic carcinoma		0	1	0	0	0	
	8240	Carcinoid tumour, NOS		0	2	2	2	0	
	8246	Neuroendocrine carcinoma, NOS		1	2	3	0	2	
	8260	Papillary adenocarcinoma, NOS		0	0	0	1	0	
	8430	Mucoepidermoid carcinoma		5	2	4	2	0	
	8480	Mucinous adenocarcinoma		0	0	1	0	0	
	8490	Signet ring cell carcinoma		1	0	0	0	0	
	8503	Intraductal papillary adenocarcinoma with invasion		0	0	0	0	1	
	8550	Acinar cell carcinoma		0	0	0	2	0	
	8583	Thymoma, type B1, malignant		0	0	0	1	0	
<b>Total</b>				<b>25</b>	<b>32</b>	<b>35</b>	<b>43</b>	<b>35</b>	
<b>XII</b>	<b>Other and unspecified malignant neoplasm</b>								
a. Other specified malignant tumours	8936	Gastrointestinal stromal sarcoma		0	0	1	0	1	
	8000	Neoplasm, malignant		11	12	19	19	19	
b. Other unspecified malignant tumours	8002	Malignant tumour, small cell type		0	1	0	0	0	
	8004	Malignant tumour, spindle cell type		0	1	3	1	3	
<b>Total</b>				<b>11</b>	<b>14</b>	<b>23</b>	<b>20</b>	<b>23</b>	

**Table 18 : Childhood cancer incidence data (0-19) Female, Sri Lanka 2015 - 2019**

Site Group	ICD -O-3 Histology		Female				
			2015	2016	2017	2018	2019
<b>I Leukaemias, myeloproliferative diseases and myelodysplastic diseases</b>							
a. Lymphoid leukaemia	9811	B lymphoblastic leukaemia/lymphoma, NOS	0	1	0	0	0
	9820	Lymphoid leukaemia, NOS	0	0	1	14	3
	9826	Burkitt cell leukaemia	0	2	0	0	0
	9835	Precursor cell lymphoblastic leukaemia, NOS	40	55	63	6	10
	9836	Precursor B-cell lymphoblastic leukaemia	15	8	0	5	8
	9837	Precursor T-cell lymphoblastic leukaemia	2	3	1	7	0
b. Acute myeloid leukaemia	9840	Acute myeloid leukaemia, M6 type	0	1	0	1	0
	9861	Acute myeloid leukaemia, NOS	15	13	11	11	7
	9866	Acute promyelocytic leukaemia, t(15;17)(q22;q11-	0	0	0	1	0
	9867	Acute myelomonocytic leukaemia	2	0	0	0	1
	9874	Acute myeloid leukaemia with maturation	5	4	2	0	0
	9891	Acute monocytic leukaemia	1	0	0	0	0
	9910	Acute megakaryoblastic leukaemia	1	0	2	0	1
c. Chronic myeloproliferative diseases	9863	Chronic myeloid leukaemia, NOS	4	2	1	2	2
d. Myelodysplastic syndrome and other myeloproliferative diseases	9946	Juvenile myelomonocytic leukaemia	0	0	1	1	1
e. Unspecified and other specified leukaemia	9801	Acute leukaemia, NOS	4	1	1	1	50
	9860	Myeloid leukaemia, NOS	0	0	0	22	0
	9930	Myeloid sarcoma	0	1	0	0	0
<b>Total</b>			<b>89</b>	<b>91</b>	<b>83</b>	<b>71</b>	<b>83</b>

**II Lymphomas and reticuloendothelial neoplasms**

a. Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	10	13	11	5	7
	9651	Hodgkin lymphoma, lymphocyte-rich	0	0	0	0	1
	9652	Hodgkin lymphoma, mixed cellularity, NOS	1	2	3	1	2
	9659	Hodgkin lymphoma, nodular lymphocyte	0	1	0	0	0
	9663	Hodgkin lymphoma, nodular sclerosis, NOS	1	4	6	4	2

Site Group	ICD -O-3 Histology	Female					
		2015	2016	2017	2018	2019	
b. Non_Hodgkin lymphomas(except Burkitt lymphoma)	9664	Hodgkin lymphoma, nodular sclerosis, cellular phase	0	0	0	0	1
	9590	Malignant lymphoma, NOS	0	0	0	0	1
	9591	Malignant lymphoma, non-Hodgkin, NOS	3	3	3	7	4
	9680	Malignant lymphoma, large B-cell, diffuse, NOS	2	1	1	2	1
	9690	Follicular lymphoma, NOS	0	0	1	0	0
	9700	Mycosis fungoides	6	2	0	4	0
	9702	Mature T-cell lymphoma, NOS	2	0	0	0	0
	9714	Anaplastic large cell lymphoma, T cell and	4	0	1	0	0
	9718	Malignant lymphoma,small B lymphocytic, NOS	0	0	0	1	0
	9727	Precursor cell lymphoblastic lymphoma, NOS	5	1	0	1	0
	9728	Precursor B-cell lymphoblastic lymphoma	1	0	0	1	0
	9729	Precursor T-cell lymphoblastic lymphoma	0	2	2	4	0
	c.Burkitt lymphoma	9687	Burkitt lymphoma, NOS	0	0	2	0
d. Miscellaneous lymphoreticular neoplasms	9750	Malignant lymphoma, NOS	0	0	0	0	2
	9751	Langerhans cell histiocytosis, NOS	0	0	3	0	0
	9754	Langerhans cell histiocytosis, disseminated	7	0	0	1	0
e.Unspecified lymphomas	9590	Malignant lymphoma, NOS	2	2	2	3	5
<b>Total</b>			<b>44</b>	<b>31</b>	<b>35</b>	<b>34</b>	<b>26</b>

### III CNS and miscellaneous intracranial and intraspinal neoplasms

a. Ependymomas and choroid plexus tumour	9390	Choroid plexus carcinoma	0	1	0	2	2
	9391	Ependymoma, NOS	2	4	2	2	0
	9392	Ependymoma, anaplastic	1	2	0	1	2
b. Astrocytoma	9380	Glioma, malignant	2	3	0	0	0
	9400	Astrocytoma, NOS	5	4	2	2	2
	9401	Astrocytoma, anaplastic	1	1	0	0	0
	9420	Fibrillary astrocytoma	0	1	0	0	0
	9424	Pleomorphic xanthoastrocytoma	1	0	1	1	1
	9430	Astroblastoma	0	0	0	0	1

Site Group	ICD -O-3 Histology		Female				
			2015	2016	2017	2018	2019
	9440	Glioblastoma, NOS	1	4	1	3	0
c. Intracranial and intraspinal embryonal tumours	9470	Medulloblastoma, NOS	5	6	4	1	5
	9471	Desmoplastic nodular medulloblastoma	0	0	1	0	0
d. Other gliomas	9380	Glioma, malignant	14	7	9	4	11
	9450	Oligodendroglioma, NOS	0	2	0	1	1
	9451	Oligodendroglioma, anaplastic	0	1	0	1	0
e. Other specified intracranial and intraspinal neoplasms	9530	Meningioma, malignant	1	0	0	0	0
f. Unspecified intracranial and intraspinal neoplasms	8000	Neoplasm, malignant	2	1	5	4	4
<b>Total</b>			<b>35</b>	<b>37</b>	<b>25</b>	<b>22</b>	<b>29</b>
<b>IV Neuroblastoma and other peripheral nervous cell tumours</b>							
a. Neuroblastoma and ganglioneuroblastoma	9490	Ganglioneuroblastoma	2	4	6	5	3
	9500	Neuroblastoma, NOS	11	13	11	5	13
b. Other peripheral nervous cell tumour	8680	Paraganglioma, malignant	0	0	1	0	0
<b>Total</b>			<b>13</b>	<b>17</b>	<b>18</b>	<b>10</b>	<b>16</b>
<b>V Retinoblastoma</b>							
	9510	Retinoblastoma, NOS	27	17	19	34	17
	9511	Retinoblastoma, differentiated	0	1	0	0	0
	9512	Retinoblastoma, undifferentiated	0	2	0	0	0
<b>Total</b>			<b>27</b>	<b>20</b>	<b>19</b>	<b>34</b>	<b>17</b>
<b>VI Renal tumours</b>							
a. Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	13	5	18	17	9
	8963	Malignant rhabdoid tumour	2	0	0	0	0
	8964	Clear cell sarcoma of kidney	0	0	0	1	1
b. Renal carcinomas	8310	Clear cell adenocarcinoma, NOS	1	0	0	0	0
	8312	Renal cell carcinoma, NOS	0	1	2	0	0
c. Unspecified malignant renal tumours	8000	Neoplasm, malignant	0	1	0	0	0
<b>Total</b>			<b>16</b>	<b>7</b>	<b>20</b>	<b>18</b>	<b>10</b>
<b>VII Hepatic tumours</b>							
a. Hepatoblastoma	8970	Hepatoblastoma	3	3	5	4	4
b. Hepatic carcinomas	8170	Hepatocellular carcinoma, NOS	0	3	1	0	0
c. Unspecified hepatic tumours	8000	Neoplasm, malignant	0	0	0	0	1



Site Group	ICD -O-3 Histology		Female				
			2015	2016	2017	2018	2019
<b>Total</b>			<b>3</b>	<b>6</b>	<b>6</b>	<b>4</b>	<b>5</b>
<b>VIII Malignant bone tumours</b>							
a. Osteosarcoma	9180	Osteosarcoma, NOS	22	19	17	11	11
	9181	Chondroblastic osteosarcoma	0	1	1	0	0
	9183	Telangiectatic osteosarcoma	0	0	1	0	0
	9186	Central Osteosarcoma	0	2	1	0	0
	9193	Periosteal osteosarcoma	2	0	0	0	0
b.Chondrosarcomas	9220	Chondrosarcoma, NOS	0	1	0	0	0
	9240	Mesenchymal chondrosarcoma	0	1	0	0	0
c. Ewing tumours and related sarcomas of bone	9260	Ewing sarcoma	15	16	14	14	3
d. Other specified malignant bone tumours	9250	Giant cell tumour of bone, malignant	0	0	0	0	2
e. Unspecified malignant bone tumours	8000	Neoplasm, malignant	1	1	0	0	0
	8800	Sarcoma, NOS	0	2	2	0	0
<b>Total</b>			<b>40</b>	<b>43</b>	<b>34</b>	<b>25</b>	<b>16</b>

#### IX Soft tissue and other extrasosseous sarcoma

a. Rhabdomyosarcoma	8900	Rhabdomyosarcoma, NOS	4	4	4	9	7
	8910	Embryonal rhabdomyosarcoma, NOS	5	6	3	5	0
	8912	Spindle cell rhabdomyosarcoma	0	1	0	0	0
	8920	Alveolar rhabdomyosarcoma	0	0	0	0	1
b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms	8811	Fibromyxosarcoma	0	3	0	1	0
	8813	Fascial fibrosarcoma	0	0	1	0	0
	8814	Infantile fibrosarcoma	1	0	0	1	0
	9540	Malignant peripheral nerve sheath tumour	3	2	1	0	1
	9560	Neurilemoma, malignant	1	0	0	0	0
d. Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumour	2	6	12	16	11
	8830	Malignant Fibrous Histiocytoma	0	0	1	0	0
	8832	Dermatofibrosarcoma, NOS	2	1	0	0	0
	8850	Liposarcoma	0	0	0	0	1

Site Group	ICD -O-3 Histology		Female				
			2015	2016	2017	2018	2019
	8854	Pleomorphic liposarcoma	1	0	1	0	0
	8890	Leiomyosarcoma, NOS	2	0	0	0	0
	8895	Myosarcoma	0	2	0	0	0
	8963	Malignant rhabdoid tumour	1	0	0	0	0
	8982	Malignant myoepithelioma	1	0	0	0	0
	9040	Synovial sarcoma, NOS	1	1	1	7	0
	9041	Synovial sarcoma, spindle cell	1	0	0	0	1
	9043	Synovial sarcoma, biphasic	0	0	0	0	1
	9044	Clear cell sarcoma, NOS(except of kidney)	0	0	0	1	0
	9120	Hemangiosarcoma	0	1	0	0	0
	9121	Cavernous haemangioma	0	1	0	0	0
	9130	Haemangioendothelioma, malignant epithelioid	1	1	1	0	0
	9133	haemangioendothelioma, malignant	0	0	0	0	1
	9170	Lymphangiosarcoma	0	1	0	0	0
	9252	Malignant tenosynovial giant cell tumour	1	0	0	0	0
	9260	Ewing sarcoma	0	1	0	2	7
	9364	Peripheral neuroectodermal tumour	0	2	0	0	0
e. Unspecified soft tissue sarcomas	8800	Sarcoma, NOS	0	1	3	1	7
	8802	Giant cell sarcoma (except of bone)	1	0	0	0	0
	8804	Epithelioid sarcoma	0	1	0	0	0
<b>Total</b>			<b>28</b>	<b>35</b>	<b>28</b>	<b>43</b>	<b>38</b>

## X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads

### a. Intracranial and intraspinal germ cell tumours

9064	Germinoma	1	2	1	0	0
9080	Teratoma, malignant NOS	0	1	0	0	0
9082	Malignant teratoma, undifferentiated	0	1	0	0	0
9085	Mixed germ cell tumour	1	0	0	0	0

### b. Malignant extracranial and extragonadal germ cell tumours

9060	Dysgerminoma	0	1	1	0	0
9064	Germinoma	0	1	0	1	0
9065	Germ cell tumour, nonseminomatous	0	0	0	0	1

Site Group	ICD -O-3 Histology		Female				
			2015	2016	2017	2018	2019
	9070	Embryonal carcinoma, NOS	0	0	0	0	1
	9071	Yolk sac tumour	5	2	2	3	1
	9080	Teratoma, malignant, NOS	2	1	1	5	0
	9085	Mixed germ cell tumour	1	0	3	0	0
	9100	Choriocarcinoma, NOS	0	2	0	0	0
c. Malignant gonadal germ cell tumours	9060	Dysgerminoma	10	8	9	2	9
	9061	Seminoma, NOS	0	0	0	0	0
	9064	Germinoma	2	3	5	2	0
	9065	Germ cell tumour, nonseminomatous	0	0	1	0	0
	9070	Embryonal carcinoma, NOS	1	1	2	0	0
	9071	Yolk sac tumour	8	7	10	3	0
	9080	Teratoma, malignant, NOS	2	3	2	7	1
	9082	Malignant teratoma, undifferentiated	0	0	0	0	0
	9085	Mixed germ cell tumour	2	1	6	0	6
	9100	Choriocarcinoma, NOS	1	2	0	2	0
d. Gonadal carcinomaa	8010	Carcinoma, NOS	0	0	0	1	0
	8140	Adenocarcinoma, NOS	0	1	0	0	0
	8441	Serous cystadenocarcinoma, NOS	0	1	3	1	2
	8450	Papillary cystadenocarcinoma, NOS	0	0	1	0	1
	8460	Papillary serous cystadenocarcinoma	0	1	0	0	0
	8472	Mucinous cystic tumour of borderline	0	2	0	0	0
	8480	Mucinous adenocarcinoma	0	2	1	1	1
e. Other and unspecified malignant gonadal tumours	8000	Neoplasm, malignant	0	1	3	1	1
	8001	Tumour cells, malignant	0	1	0	0	0
	8590	Sex cord-gonadal stromal tumor, NOS	0	0	0	1	0
	8620	Granulosa cell tumour, malignant	2	1	2	1	1
	8622	Granulosa cell tumour, juvenile	0	1	0	0	0
	8631	Sertoli-Leydig cell tumour, poorly differentiate	1	0	1	0	1
Total			39	47	54	31	26

## XI Other malignant epithelial neoplasms and malignant melanomas

a. Adrenocortical carcinoms	8370	Adrenal cortical carcinoma	0	1	0	1	0
-----------------------------	------	----------------------------	---	---	---	---	---

Site Group	ICD -O-3 Histology		Female				
			2015	2016	2017	2018	2019
b. Thyroid carcinomas	8050	Papillary carcinoma, NOS	0	13	4	4	7
	8260	Papillary adenocarcinoma, NOS	40	32	29	30	29
	8290	Oxyphilic adenocarcinoma	0	4	1	0	3
	8330	Follicular adenocarcinoma, NOS	2	5	10	8	12
	8331	Follicular adenocarcinoma, well differentiated	0	0	0	1	0
	8335	Follicular carcinoma, minimally invasive	1	3	1	2	1
	8340	Papillary carcinoma, follicular variant	9	7	5	6	7
	8341	Papillary microcarcinoma	1	2	3	6	4
	8343	Papillary carcinoma, encapsulated	1	1	0	1	0
	8346	Mixed medullary-follicular carcinoma	0	0	1	0	0
	8510	Medullary carcinoma, NOS	2	1	0	0	0
c. Nasopharyngeal carcinomas	8010	Carcinoma, NOS	0	3	0	2	0
	8070	Squamous cell carcinoma, NOS	0	0	1	0	0
d. Malignant melanomas	8720	Malignant melanoma, NOS (except juvenile melanoma)	5	1	1	0	0
	8744	Acral lentiginous melanoma, Malignant	0	0	1	0	0
e. Skin carcinomas	8031	Giant cell carcinoma	0	0	0	0	1
	8070	Squamous cell carcinoma, NOS	0	0	1	0	1
	8320	Granular cell carcinoma	0	0	0	1	0
	8390	Skin appendage carcinoma	0	0	0	0	1
	8097	Basal cell carcinoma, nodular	1	0	0	0	0
f. Other and unspecified carcinomas	8010	Carcinoma, NOS	0	2	1	2	4
	8033	Pseudo sarcomatous carcinoma	0	2	0	0	0
	8070	Squamous cell carcinoma, NOS	0	1	4	2	3
	8130	Papillary transitional cell carcinoma	0	2	0	0	0
	8140	Adenocarcinoma, NOS	0	2	1	1	3
	8200	Adenoid cystic carcinoma	1	1	0	0	0
	8240	Carcinoid tumour, NOS	0	1	0	0	0
	8246	Neuroendocrine carcinoma, NOS	2	0	1	2	7
	8260	Papillary adenocarcinoma, NOS	1	0	0	2	0

Site Group	ICD -O-3 Histology	Female				
		2015	2016	2017	2018	2019
	8430 Mucoepidermoid carcinoma	2	3	6	5	0
	8452 Solid pseudopapillary carcinoma	0	4	1	0	0
	8470 Mucinous cystadenocarcinoma, NOS	0	0	0	0	2
	8480 Mucinous Adenocarcinoma	0	0	1	1	0
	8500 Infiltrating duct carcinoma	0	1	0	1	0
	8502 Secretory carcinoma of breast	0	1	1	0	0
	8503 Intraductal papillary adenocarcinoma with invasion	0	0	1	1	0
	8521 Infiltrating ductular carcinoma	0	1	0	0	0
	8550 Acinar cell carcinoma	0	0	0	1	0
	9020 Phyllodes tumour, malignant	0	0	0	1	0

Total		68	94	75	81	85
-------	--	----	----	----	----	----

## XII Other and unspecified malignant neoplasms

a. Other specified malignant tumours	8935 Stromal sarcoma, NOS	0	0	1	0	1
	8936 Gastrointestinal stromal sarcoma	0	0	0	1	0
	8950 Mullerian mixed tumour	1	0	0	0	0
	9110 Mesonephroma, malignant	0	0	0	2	0
b. Other unspecified malignant tumours	8000 Neoplasm, malignant	11	12	13	6	13
	8002 Malignant tumour, small cell type	0	1	0	0	0
	8004 Malignant tumour, spindle cell type	0	1	2	4	2
Total		12	14	16	13	16

## 2. Population Based Cancer Registry Colombo District 2012 - 2019



DATA REPORT





**Table 19 : Distribution of incidence of 0-19 year old childhood cancer patients by 5 year age groups in Colombo district 2012 -2019**

Year	0-4	05-09	10-14	15-19	Total Childhood Cancer Incidence - Colombo District	Total Childhood Cancer Incidence - Sri Lanka	% of Colombo district cases out of total incident childhood cancers Sri Lanka
2012	30	16	11	23	<b>80</b>	687	<b>11.6</b>
2013	22	13	13	30	<b>78</b>	669	<b>11.7</b>
2014	37	25	15	33	<b>110</b>	739	<b>14.9</b>
2015	31	20	24	27	<b>102</b>	814	<b>12.5</b>
2016	20	15	21	33	<b>89</b>	918	<b>9.7</b>
2017	43	17	26	36	<b>122</b>	862	<b>14.2</b>
2018	30	13	20	22	<b>85</b>	766	<b>11.1</b>
2019	48	42	18	25	<b>133</b>	780	<b>17.1</b>

**Table 20: Distribution of deaths of 0-19 year old childhood cancer patients by 5 year age groups in Colombo district 2012 -2019**

Year	0-4	05-09	10-14	15-19	Total number of Childhood cancer deaths - Colombo district	Total Childhood Cancer Deaths in Sri Lanka	% of Colombo district deaths out of total childhood cancer deaths Sri Lanka
2012	3	1	2	6	<b>12</b>	275	<b>4.4</b>
2013	1	1	1	4	<b>6</b>	223	<b>2.7</b>
2014	2	3	2	9	<b>14</b>	269	<b>5.2</b>
2015	3	1	4	7	<b>12</b>	Not available	
2016	2	3	4	3	<b>10</b>	Not available	
2017	11	5	6	7	<b>18</b>	Not available	
2018	3	4	8	5	<b>17</b>	Not available	
2019	3	4	8	5	<b>17</b>	Not available	






Figure 18 : Crude incidence rate & Crude mortality rate for 0-19 year old Childhood cancers in Colombo district, Sri Lanka 2012-2019




Figure 19 : Age standardized incidence rate & mortality rate for 0-19 year old Childhood cancers in Colombo district, Sri Lanka 2012-2019

# 3. Hospital Based Cancer Registry -2020 of National Cancer Institute, Maharagama, Sri Lanka




DATA REPORT






**Table 21: Childhood and adolescent cancer incidence data by sex and site, National Cancer Institute, Maharagama 2020**

ICCC site	Male	Female	Total
<b>I</b> Leukaemias, myeloproliferative diseases and myelodysplastic diseases	155	100	255
<b>II</b> Lymphomas and reticuloendothelial neoplasms	31	16	47
<b>III</b> CNS and miscellaneous intracranial and intraspinal neoplasms	28	28	56
<b>IV</b> Neuroblastoma and other peripheral nervous cell tumours	4	13	17
<b>V</b> Retinoblastoma	10	9	19
<b>VI</b> Renal tumours	7	10	17
<b>VII</b> Hepatic tumours	6	3	9
<b>VIII</b> Malignant bone tumours	32	18	50
<b>IX</b> Soft tissue and other extraosseous sarcoma	12	8	20
<b>X</b> Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	8	28	36
<b>XI</b> Other malignant epithelial neoplasms and malignant melanomas	6	9	15
<b>XII</b> Other and unspecified malignant neoplasms	4	5	9
<b>Total</b>	<b>303</b>	<b>247</b>	<b>550</b>



**Figure 20: Proportion of childhood and adolescent cancers in males, in National Cancer Institute Maharagama 2020**



**Figure 21: Proportion of childhood and adolescent cancers in females, in National Cancer Institute Maharagama 2020**

**Table 22: Childhood and adolescent cancer incidence data (0-19) male - National Cancer Institute Maharagama 2020**

ICCC site	ICD O Histology	00-04	05-09	10-14	15-19	Total
<b>I Leukaemias, myeloproliferative diseases and myelodysplastic diseases</b>						
a.Lymphoid leukaemia	9835 Precursor cell lymphoblastic leukaemia, NOS	0	0	1	1	2
	9836 Precursor B-cell lymphoblastic leukaemia	44	21	10	4	79
	9837 Precursor T-cell lymphoblastic leukaemia	3	13	17	10	43
b.Acute myeloid leukaemia	9840 Acute myeloid leukaemia, M6 type	1	0	0	0	1
	9861 Acute myeloid leukaemia, NOS	15	2	2	1	20
	9891 Acute monocytic leukaemia	0	1	1	0	2
	9910 Acute megakaryoblastic leukemia	1	0	0	0	1
c.Chronic myeloproliferative diseases	9863 Chronic myeloid leukaemia, NOS	2	0	0	1	3
d.Myelodysplastic syndrome and other myeloproliferative diseases	9946 Juvenile myelomonocytic leukaemia	2	0	0	0	2
	9989 Myelodysplastic syndrome, NOS	0	1	0	0	1
e. Unspecified and other specified leukaemia	9801 Acute leukaemia, NOS	0	1	0	0	1
<b>Total</b>		<b>68</b>	<b>39</b>	<b>31</b>	<b>17</b>	<b>155</b>
<b>II Lymphomas and reticuloendothelial neoplasms</b>						
a. Hodgkin lymphomas	9650 Hodgkin lymphoma, NOS	0	1	4	1	6
b.Non_Hodgkin lymphomas(except Burkitt lymphoma)	9690 Follicular lymphoma, NOS	1	0	0	0	1
	9700 Mycosis fungoides	1	0	0	0	1
	9702 Mature T-cell lymphoma, NOS	0	0	0	1	1
	9714 Anaplastic large cell lymphoma, T cell and	0	2	2	1	5

ICCC site	ICD O Histology	00-04	05-09	10-14	15-19	Total
	9729 Precursor T-cell lymphoblastic lymphoma	0	0	1	1	2
	9731 plasmacytoma, NOS	0	1	0	0	1
c. Burkitt lymphoma	9687 Burkitt lymphoma, NOS	0	0	3	0	3
d. Miscellaneous lymphoreticular neoplasms	9754 Langerhans cell histiocytosis, disseminated	5	1	2	1	9
e. Unspecified lymphomas	9590 Malignant lymphoma, NOS	0	1	0	0	1
<b>Total</b>		<b>7</b>	<b>6</b>	<b>12</b>	<b>5</b>	<b>30</b>

### III CNS and miscellaneous intracranial and intraspinal neoplasms

a. Ependymomas and choroid plexus tumour	9391	Ependymoma, NOS	1	0	1	0	2
	9392	Ependymoma, anaplastic	1	0	0	0	1
b. Astrocytoma	9380	Glioma, malignant	1	1	2	0	4
	9400	Astrocytoma, NOS	0	0	1	0	1
	9401	Astrocytoma, anaplastic	1	1	0	0	2
	9441	Giant cell glioblastoma	0	1	0	0	1
	9442	Gliosarcoma	0	0	0	1	1
c. Intracranial and intraspinal embryonal tumours	9470	Medulloblastoma, NOS	3	2	1	0	6
	9473	Primitive neuroectodermal tumor, NOS	1	1	0		2
d. Other gliomas	9380	Glioma, malignant	2	3	0	1	6
	9451	Oligodendroglioma, anaplastic	0	0	0	1	1
e. Other specified intracranial and intraspinal neoplasms	9362	Pineoblastoma	0	1	0	0	1
	9350	Craniopharyngioma	0	0	1	0	1
<b>Total</b>			<b>10</b>	<b>10</b>	<b>6</b>	<b>3</b>	<b>28</b>

ICCC site	ICD O Histology	00-04	05-09	10-14	15-19	Total
<b>IV Neuroblastoma and other peripheral nervous cell tumours</b>						
a. Neuroblastoma and ganglioneuroblastom	9490 Ganglioneuroblastoma	1	0	0	0	1
	9500 Neuroblastoma, NOS	3	0	0	0	3
<b>Total</b>		<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4</b>
<b>V Retinoblastoma</b>						
Retinoblastoma	9510 Retinoblastoma, NOS	10	0	0	0	10
<b>Total</b>		<b>10</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>10</b>
<b>VI Renal tumours</b>						
a. Nephroblastoma and other nonepithelial renal tumours	8960 Nephroblastoma, NOS	7	0	0	0	7
<b>Total</b>		<b>7</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>7</b>
<b>VII Hepatic tumours</b>						
a.Hepatoblastoma	8970 Hepatoblastoma	6	0	0	0	6
<b>Total</b>		<b>6</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>6</b>
<b>VIII Malignant bone tumours</b>						
a. Osteosarcoma	9180 Osteosarcoma, NOS	0	0	10	10	20
	9181 Chondroblastic osteosarcoma	0	0	1	0	1
c. Ewing tumours and related sarcomas of bone	9260 Ewing sarcoma	2	2	4	3	11
e. Unspecified malignant bone tumours	8000 Neoplasm, malignant	0	0	1	0	1
<b>Total</b>		<b>2</b>	<b>2</b>	<b>16</b>	<b>13</b>	<b>33</b>
<b>IX Soft tissue and other extraosseous sarcoma</b>						
a. Rhabdomyosarcoma	8900 Rhabdomyosarcoma NOS	2	1	0	1	4
b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms	9150 Heamangiopericytoma	0	1	1	0	2
	9580 Granular cell, tumour malignant	1	0	0	0	1



ICCC site		ICD O Histology		00-04	05-09	10-14	15-19	Total	
	d. Other specified soft tissue sarcomas	9040	Synovial sarcoma, NOS	1	0	2	0	3	
	e. Unspecified soft tissue sarcomas	8804	Epithelioid sarcoma	0	0	0	1	1	
<b>Total</b>				<b>4</b>	<b>2</b>	<b>3</b>	<b>2</b>	<b>11</b>	
<b>X</b>	Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	a. Intracranial and intraspinal germ cell tumours	9064	Germinoma	0	0	2	0	2
		b. Malignant extracranial and extragonadal germ cell tumours	9064	Germinoma	1	0	0	0	1
			9071	Yolk sac tumor	0	0	0	1	1
			9080	Teratoma, malignant NOS	1	1	0	0	2
		c. Malignant gonadal germ cell tumours	9080	Teratoma, malignant NOS	1	0	0	0	1
		e. Other and unspecified malignant gonadal tumours	8000	Neoplasm, malignant	0	0	1	0	1
<b>Total</b>				<b>3</b>	<b>1</b>	<b>3</b>	<b>1</b>	<b>8</b>	
<b>XI</b>	Other malignant epithelial neoplasms and malignant melanomas	a. Adrenocortical carcinomas	8370	Adrenal cortical carcinoma	0	0	1	1	2
		f. Other and unspecified carcinomas	8070	Squamous cell carcinoma, NOS	0	0	0	1	1
			8246	Neuroendocrine carcinoma, NOS	0	0	1	0	1
			8380	Endometroid Adenocarcinoma	0	1	1	0	2
<b>Total</b>				<b>0</b>	<b>1</b>	<b>3</b>	<b>2</b>	<b>6</b>	

ICCC site		ICD O Histology		00-04	05-09	10-14	15-19	Total	
XII	Other and unspecified malignant neoplasms	b. Other unspecified malignant tumours	8000	Neoplasm, malignant	0	0	1	2	3
			8004	Malignant tumor, spindle cell type	0	0	1	0	1
<b>Total</b>				<b>0</b>	<b>0</b>	<b>2</b>	<b>2</b>	<b>4</b>	
<b>Total</b>				<b>121</b>	<b>61</b>	<b>76</b>	<b>45</b>	<b>303</b>	

**Table 23 : Childhood and adolescent cancer incidence data (0-19) Female, National Cancer Institute Maharashtra 2020**

ICCC site		ICD O Morphology		00-04	05-09	10-14	15-19	Total	
I	Leukemias, myeloproliferative diseases, and myelodysplastic diseases	a. Lymphoid leukaemia	9836	Precursor B-cell lymphoblastic leukaemia	37	15	9	5	66
			9837	Precursor T-cell lymphoblastic leukaemia	1	2	3	1	7
		b. Acute myeloid leukaemia	9840	Acute myeloid leukaemia, M6 type	1	0	0	0	1
			9861	Acute myeloid leukaemia, NOS	6	5	6	4	21
			9867	Acute myelomonocytic leukaemia, NOS	1	0	0	0	1
		c. Chronic myeloproliferative diseases	9863	Chronic myeloid leukaemia, NOS	0	1	0	0	1
		d. Myelodysplastic syndrome and other myeloproliferative diseases	9989	Myelodysplastic syndrome, NOS	1	0	0	0	1
		e. Unspecified and other specified leukaemia	9860	Myeloid leukemia, NOS	1	0	0	0	1
			9898	Myeloid leukemia associated with Down Syndrome	1	0	0	0	1
						<b>49</b>	<b>23</b>	<b>18</b>	<b>10</b>
II	Lymphomas and reticuloendothelial neoplasms	a. Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	0	1	3	0	4
		b. Non_Hodgkin lymphomas(except Burkitt lymphoma)	9714	Anaplastic large cell lymphoma, T cell Null cell	0	0	1	1	2
			9729	Precursor T-cell lymphoblastic lymphoma	0	0	1	0	1
		c. Burkitt lymphoma	9687	Burkitt lymphoma, NOS	0	1	0	0	1
		d. Miscellaneous lymphoreticular neoplasms	9754	Langerhans cell histiocytosis, disseminated	3	1	0	0	4
<b>Total</b>				<b>3</b>	<b>4</b>	<b>6</b>	<b>3</b>	<b>16</b>	

ICCC site		ICD O Morphology		00-04	05-09	10-14	15-19	Total	
III	CNS and miscellaneous intracranial and intraspinal neoplasms	a. Ependymomas and choroid plexus tumour	9391	Ependymoma, NOS	0	1	0	0	1
			9392	Ependymoma, anaplastic	2	0	2	0	4
		b. Astrocytoma	9380	Glioma, malignant	0	1	1	0	2
			9400	Astrocytoma, NOS	2	0	0	1	3
			9401	Astrocytoma, anaplastic	0	0	0	2	2
		c. Intracranial and intraspinal embryonal tumours	9470	Medulloblastoma, NOS	4	2	1	1	8
			9473	Primitive neuroectodermal tumor, NOS	0	0	1	0	1
		d. Other gliomas	9380	Glioma, malignant	1	4	1	0	6
			9450	Oligodendroglioma NOS	0	0	1	0	1
		e. Other specified intracranial and intraspinal neoplasms	9350	Craniopharyngioma	0	1	1	1	3
					0	1	1	1	3
<b>Total</b>				<b>9</b>	<b>9</b>	<b>8</b>	<b>5</b>	<b>31</b>	
IV	Neuroblastoma and other peripheral nervous cell tumours	a. Neuroblastoma and ganglioneuroblastoma	9490	Ganglioneuroblastoma	3	1	0	0	4
			9500	Neuroblastoma, NOS	5	3	1	0	9
<b>Total</b>				<b>8</b>	<b>4</b>	<b>1</b>	<b>0</b>	<b>13</b>	
V	Retinoblastoma	Retinoblastoma	9510	Retinoblastoma, NOS	8	1	0	0	9
<b>Total</b>				<b>8</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>9</b>	
VI	Renal tumours	a. Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	6	3	0	0	9
			8963	Malignant rhabdoid tumor	1	0	0	0	1
<b>Total</b>				<b>7</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>10</b>	

ICCC site			ICD O Histology		00-04	05-09	10-14	15-19	Total
VII	Hepatic tumours	a. Hepatoblastoma	8970	Hepatoblastoma	3	0	0	0	3
<b>Total</b>					<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3</b>
VIII	Malignant bone tumours	a. Osteosarcoma	9180	Osteosarcoma, NOS	0	0	3	6	9
			9181	Chondroblastic osteosarcoma	0	0	1	0	1
		c. Ewing tumours and related sarcomas of bone	9260	Ewing sarcoma	2	2	4	0	8
<b>Total</b>					<b>2</b>	<b>2</b>	<b>8</b>	<b>6</b>	<b>18</b>
IX	Soft tissue and other extrasosseous sarcoma	a. Rhabdomyosarcoma	8900	Rhabdomyosarcoma, NOS	0	1	0	0	1
		d. Other specified soft tissue sarcomas	9040	Synovial sarcoma, NOS	0	0	1	3	4
			9180	Osteosarcoma, NOS	0	1	0	0	1
			9260	Ewing sarcoma	0	1	1	0	2
<b>Total</b>					<b>0</b>	<b>3</b>	<b>2</b>	<b>3</b>	<b>8</b>
X	Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	a. Intracranial and intraspinal germ cell tumours	9064	Germinoma	0	0	1	0	1
		b. Malignant extracranial and extragonadal germ cell tumours	9071	Yolk sac tumor	2	0	0	0	2
			9080	Teratoma, malignant NOS	1	1	0	0	2
			9060	Dysgerminoma	0	1	3	1	5
		c. Malignant gonadal germ cell tumours	9064	Germinoma	1	0	1	0	2
			9071	Yolk sac tumor	0	0	1	1	2
			9080	Teratoma, malignant NOS	3	1	1	1	6
			9085	Mixed germ cell tumour	0	0	3	2	5
		Gonadal carcinoma	8471	Papillary mucinous cyctadenocarcinoma	0	0	0	1	1
<b>Total</b>					<b>7</b>	<b>3</b>	<b>9</b>	<b>6</b>	<b>25</b>

ICCC site		ICD O Histology		00-04	05-09	10-14	15-19	Total
	e. Other and unspecified malignant gonadal tumours	8620	Granulosa cell tumor	0	0	2	0	2
<b>Total</b>				<b>7</b>	<b>3</b>	<b>12</b>	<b>6</b>	<b>28</b>
XI	Other malignant epithelial neoplasms and malignant melanomas	a. Adrenocortical carcinoms	8370 Adrenocortical carcinoms	1	1	0	0	2
		b. Thyroid carcinoma	8260 Papillary adenocarcinoma	0	0	2	2	4
			8340 Papillary carcinoma, follicular variant	0	0	0	1	1
		f. Other and unspecified carcinomas	8380 Endometroid adenocarcinoma	0	1	0	0	1
			8430 Mucoepidermoid carcinoma	0	1	0	0	1
<b>Total</b>				<b>1</b>	<b>3</b>	<b>2</b>	<b>3</b>	<b>9</b>
XII	Other and unspecified malignant neoplasms	b. Other specified malignant tumours	8973 Pleuropulmonary blastoma	1	0	0	0	1
		b. Other unspecified malignant tumours	8000 Neoplasm, malignant	0	0	1	1	2
			8004 Malignant tumor, spindle cell type	1	0	0	0	1
			8825	0	1	0	0	1
<b>Total</b>				<b>2</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>5</b>
<b>Total</b>				<b>99</b>	<b>55</b>	<b>57</b>	<b>36</b>	<b>247</b>

**Table 24 : Distribution of childhood cancers among 0-19 years - National Cancer Institute Sri Lanka (Apeksha Hospital) in 2020 according to district**

Province	District	Male	Female	Total
Western	Colombo	30	27	57
	Gampaha	36	28	64
	Kalutara	21	24	45
Central	Kandy	15	20	35
	Matale	8	4	12
	Nuwara Eliya	6	5	11
Southern	Galle	18	13	31
	Hambantota	14	5	19
	Matara	13	11	24
Northern	Jaffna	3	5	8
	Kilinochchi	1	0	1
	Mannar	2	0	2
	Mullaitivu	1	4	5
	Vavuniya	2	2	4
Eastern	Ampara	11	10	21
	Batticaloa	4	8	12
	Trincomalee	7	6	13
North Western	Kurunegala	23	13	36
	Puttalam	10	11	21
North Central	Anuradhapura	19	9	28
	Polonnaruwa	6	4	10
Uva	Badulla	17	8	25
	Moneragala	5	4	9
Sabaragamuwa	Kegalle	8	8	16
	Ratnapura	16	13	29
District not known		7	5	12
<b>Total</b>		<b>303</b>	<b>247</b>	<b>550</b>

## Deaths due to Childhood Cancers at National Cancer Institute, Sri Lanka in year 2020

Table 25: Distribution of childhood cancer deaths occurred at National Cancer Institute by sex and 5 year age groups in year 2020

Age Group	Sex		Total
	Male	Female	
0-4	13 (50%)	13 (50%)	26
5-9	7 (44%)	9 (56%)	16
10-14	16 (76%)	5 (24%)	21
15-19	11 (65%)	6 (35%)	17
Age not known	2 (40%)	3 (60%)	5
<b>Total</b>	<b>49 (57%)</b>	<b>36 (43%)</b>	<b>85</b>



**Table 26 Distribution of childhood cancer deaths occurred at National Cancer Institute by sex and ICCC -3 categories in year 2020**

No and ICCC-3	Male		Female		Total
	No.	%	No.	%	
I Leukaemias, myeloproliferative diseases, and myelodysplastic diseases	38	70%	16	30%	54
II Lymphomas and reticuloendothelial neoplasms	1	17%	5	83%	6
III CNS and miscellaneous intracranial and intraspinal neoplasms	1	33%	2	67%	3
IV Neuroblastoma and other peripheral nervous cell tumours	1	25%	3	75%	4
V Retinoblastoma	0	0	0	0	0
VI Renal tumours	0	0	2	100%	2
VII Hepatic tumours	0	0	3	100%	3
VIII Malignant bone tumours	3	60%	2	40%	5
IX Soft tissue and other extraosseous sarcoma	3	75%	1	25%	4
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	0	0	2	100%	2
XI Other malignant epithelial neoplasms and malignant melanomas	0	0	0	0	0
XII Other and unspecified malignant neoplasms	2	100%	0	0	2
<b>Total</b>	<b>49</b>	<b>58%</b>	<b>36</b>	<b>42%</b>	<b>85</b>

## 4.Pathology Based Cancer Registry- 2020

### (1) Lady Ridgeway Hospital for Children, Colombo



### (2) Sirimavo Bandaranayake Specialized Children Hospital, Peradeniya



**Table 27: Childhood cancer cases in ICCC code and histology by sex in 2020 - Lady Ridgway Hospital for Children**

ICCC sites		ICD-O-3 Histology		Male	Female	Total	
<b>I</b>	<b>Leukaemias, myeloproliferative diseases, and myelodysplastic diseases</b>	a. Lymphoid leukaemia	9835	Precursor cell lymphoblastic leukemia, NOS	12	12	24
			9836	Precursor B -cell lymphoblastic leukemia, NOS	1	0	1
			9837	Precursor B -cell lymphoblastic leukemia, NOS	1	0	1
		c. Chronic myeloproliferative diseases	9863	Chronic myeloid leukemia, NOS	1	0	1
		d. Myelodysplastic syndrome and other myeloproliferative diseases	9946	Juvenile myelomonocytic leukemia	2	0	2
		e. Unspecified and other specified leukaemia	9801	Acute leukemia, NOS	1	3	4
			9860	Myeloid leukemia, NOS	1	0	1
<b>Total</b>				<b>19</b>	<b>15</b>	<b>34</b>	
<b>II</b>	<b>Lymphomas and reticuloendothelial neoplasms</b>	b. Non_Hodgkin lymphomas(except Burkitt lymphoma)	9680	Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1
			9714	Anaplastic large cell lymphoma	1	0	1
		c. Burkitt lymphoma	9687	c. Burkitt lymphoma	1	0	1
		d. Miscellaneous lymphoreticular neoplasms	9754	Langerhan cell histiocytosis	2	1	3
		e. Unspecified lymphomas	9590	Malignant lymphoma, NOS	0	1	1
<b>Total</b>				<b>5</b>	<b>2</b>	<b>7</b>	
<b>IV</b>	<b>Neuroblastoma and other peripheral nervous cell tumours</b>	a. Neuroblastoma and ganglioneuroblastoma	9490	Ganglioneuroblastoma	1	2	3
			9500	Neuroblastoma, NOS	3	5	8
<b>Total</b>				<b>4</b>	<b>7</b>	<b>11</b>	

ICCC sites		ICD-O-3 Histology		Male	Female	Total	
VI	<b>Renal tumours</b>	a. Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	4	5	9
		c. Unspecified malignant renal tumours	8960	Nephroblastoma, NOS	0	1	1
		<b>Total</b>			<b>4</b>	<b>6</b>	<b>10</b>
VII	<b>Hepatic tumours</b>	a. Hepatoblastoma	8970	Hepatoblastoma	3	2	5
		<b>Total</b>			<b>3</b>	<b>2</b>	<b>5</b>
VIII	<b>Malignant bone tumours</b>	a. Osteosarcoma	9180	Osteosarcoma, NOS	1	2	3
		c. Ewing tumours and related sarcomas of bone	9260	Ewing sarcoma	4	3	7
		d. Other specified malignant bone tumours	9250	Giant cell tumor of bone, malignant	0	1	1
		<b>Total</b>			<b>5</b>	<b>6</b>	<b>11</b>
IX	<b>Soft tissue and other extraosseous sarcoma</b>	b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms	9540	Malignant peripheral nerve sheath tumor	1	0	1
		d. Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumor	4	3	7
		e. Unspecified soft tissue sarcomas	8801	Spindle cell sarcoma	0	1	1
		<b>Total</b>			<b>5</b>	<b>4</b>	<b>9</b>
X	<b>Germ cell tumours, trophoblastic tumours, and neoplasms of gonads</b>	b. Malignant extracranial and extragonadal germ cell tumours	9085	Mixed germ cell tumor	0	1	1
		c. Malignant gonadal germ cell tumours	9064	Germinoma	0	1	1
			9085	Mixed germ cell tumor	0	1	1
		<b>Total</b>			<b>0</b>	<b>3</b>	<b>3</b>
XI	<b>Other malignant epithelial neoplasms and malignant melanomas</b>	f. Other and unspecified carcinomas	8430	Mucoepidermoid carcinoma	0	1	1
		<b>Total</b>			<b>0</b>	<b>1</b>	<b>1</b>
<b>Total</b>				<b>45</b>	<b>46</b>	<b>91</b>	

ICCC sites		ICD-O-3 Histology		Male	Female	Total	
<b>I</b>	<b>Leukaemias, myeloproliferative diseases, and myelodysplastic diseases</b>	a. Lymphoid leukaemia	9835	Precursor cell lymphoblastic leukemia, NOS	12	12	24
			9836	Precursor B -cell lymphoblastic leukemia, NOS	1	0	1
			9837	Precursor B -cell lymphoblastic leukemia, NOS	1	0	1
		c.Chronic myeloproliferative diseases	9863	Chronic myeloid leukemia,NOS	1	0	1
		d. Myelodysplastic syndrome and other myeloproliferative diseases	9946	Juvenile myelomonocytic leukemia	2	0	2
		e. Unspecified and other specified leukaemia	9801	Acute leukemia, NOS	1	3	4
		9860	Myeloid leukemia,NOS	1	0	1	
<b>Total</b>				<b>19</b>	<b>15</b>	<b>34</b>	
<b>II</b>	<b>Lymphomas and reticuloendothelial neoplasms</b>	b. Non_Hodgkin lymphomas(except Burkitt lymphoma)	9680	Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1
			9714	Anaplastic large cell lymphoma	1	0	1
		c.Burkitt lymphoma	9687	c.Burkitt lymphoma	1	0	1
		d. Miscellaneous lymphoreticular neoplasms	9754	Langerhan cell histiocytosis	2	1	3
		e.Unspecified lymphomas	9590	Malignant lymphoma, NOS	0	1	1
<b>Total</b>				<b>5</b>	<b>2</b>	<b>7</b>	
<b>IV</b>	<b>Neuroblastoma and other peripheral nervous cell tumours</b>	a. Neuroblastoma and ganglioneuroblastom	9490	Ganglioneuroblastoma	1	2	3
			9500	Neuroblastoma, NOS	3	5	8
<b>Total</b>				<b>4</b>	<b>7</b>	<b>11</b>	
<b>VI</b>	<b>Renal tumours</b>	a. Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	4	5	9

ICCC sites		ICD-O-3 Histology		Male	Female	Total	
		c. Unspecified malignant renal tumours	8960	Nephroblastoma, NOS	0	1	1
<b>Total</b>				<b>4</b>	<b>6</b>	<b>10</b>	
<b>VII</b>	<b>Hepatic tumours</b>	a. Hepatoblastoma	8970	Hepatoblastoma	3	2	5
<b>Total</b>				<b>3</b>	<b>2</b>	<b>5</b>	
<b>VIII</b>	<b>Malignant bone tumours</b>	a. Osteosarcoma	9180	Osteosarcoma, NOS	1	2	3
		c. Ewing tumours and related sarcomas of bone	9260	Ewing sarcoma	4	3	7
		d. Other specified malignant bone tumours	9250	Giant cell tumor of bone, malignant	0	1	1
<b>Total</b>				<b>5</b>	<b>6</b>	<b>11</b>	
<b>IX</b>	<b>Soft tissue and other extrasosseous sarcoma</b>	b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms	9540	Malignant peripheral nerve sheath tumor	1	0	1
		d. Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumor	4	3	7
		e. Unspecified soft tissue sarcomas	8801	Spindle cell sarcoma	0	1	1
<b>Total</b>				<b>5</b>	<b>4</b>	<b>9</b>	
<b>X</b>	<b>Germ cell tumours, trophoblastic tumours, and neoplasms of gonads</b>	b. Malignant extracranial and extragonadal germ cell tumours	9085	Mixed germ cell tumor	0	1	1
			9064	Germinoma	0	1	1
		c. Malignant gonadal germ cell tumours	9085	Mixed germ cell tumor	0	1	1
<b>Total</b>				<b>0</b>	<b>3</b>	<b>3</b>	
<b>XI</b>	<b>Other malignant epithelial neoplasms and malignant melanomas</b>	f. Other and unspecified carcinomas	8430	Mucoepidermoid carcinoma	0	1	1
<b>Total</b>				<b>0</b>	<b>1</b>	<b>1</b>	
<b>Total</b>				<b>45</b>	<b>46</b>	<b>91</b>	

**Table 28: Childhood cancer cases by sex in 2020 - Sirimavo Bandaranayake Memorial Children Hospital**

ICCC sites		ICD -O-3 Histology		Male	Female	Total	
I	<b>Leukaemias, myeloproliferative diseases, and myelodysplastic diseases</b>	a. Lymphoid leukaemia	9835	Precursor cell lymphoblastic leukemia, NOS	8	1	9
II	<b>Lymphomas and reticuloendothelial neoplasms</b>	b. Non_Hodgkin lymphomas(except Burkitt lymphoma)	9591	Malignant lymphoma, non-Hodgkin,NOS	2	1	3
		c.Burkitt lymphoma	9687	Burkitt lymphoma, NOS	0	1	1
IV	<b>Neuroblastoma and other peripheral nervous cell tumours</b>	a. Neuroblastoma and ganglioneuroblastom	9490	Ganglioneuroblastoma	1	0	1
			9500	Neuroblastoma, NOS	1	1	2
VI	<b>Renal tumours</b>	a. Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	2	2	4
VII	<b>Hepatic tumours</b>	b. Hepatic carcinomas	8010	Carcinoma, NOS	1	0	1
VIII	<b>Malignant bone tumours</b>	c. Ewing tumours and related sarcomas of bone	9260	Ewing sarcoma	1	0	1
IX	<b>Soft tissue and other extraosseous sarcoma</b>	a. Rhabdomyosarcoma	8910	Embryonal rhabdomyosarcoma, NOS	0	1	1
		d. Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumor	3	1	4
XI	<b>Other malignant epithelial neoplasms and malignant melanomas</b>	b. Thyroid carcinomas	8260	Papillary adenocarcinoma, NOS	0	1	1
			8330	Follicular adenocarcinoma, NOS	0	1	1
<b>Total</b>					<b>19</b>	<b>10</b>	<b>29</b>



# 5. Mortality of childhood cancers based on existing evidence of 'Civil Registration System in Sri Lanka'







**Table 29: Distribution of Cancer related deaths among 0-19 males & females by 5 year age groups in Sri Lanka 2010-2014**

Age group	2010		2011		2012		2013		2014	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
0-4	32	36	36	37	36	37	29	36	34	30
5-9	32	27	26	26	33	18	22	13	33	25
10-14	38	22	31	31	31	31	27	24	39	28
15-19	52	35	55	34	55	34	42	30	44	36
<b>Total</b>	<b>154</b>	<b>120</b>	<b>148</b>	<b>128</b>	<b>155</b>	<b>120</b>	<b>120</b>	<b>103</b>	<b>150</b>	<b>119</b>



**Figure 22: Number of Childhood & Adolescent Cancer Related deaths among 0-19 year old males and females in Sri Lanka 2010 -2014**

**Table 30: Distribution of childhood cancer deaths by ICD 10 site among 0-19 year old males for year 2010-2014**

<b>1-026 Neoplasms C00-D48</b>	<b>2010</b>	<b>2011</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>
1-027 Malignant neoplasm of lip,oral cavity and pharynx	1	2	1	2	1
1-028 Malignant neoplasm of oesophagus C15	2	0	0	0	0
1-029 Malignant neoplasm of stomach C16	2	2	2	1	0
1-030 Malignant neoplasm of colon,rectum and anus C18-C21	1	3	3	0	0
1-031 Malignant neoplasm of liver and intrahepatic bile ducts	3	2	2	3	3
1-032 Malignant neoplasm of pancreas C25	2	1	1	0	0
1-033 Malignant neoplasm of larynx C32	0	1	2	0	0
1-034 Malignant neoplasm of trachea, bronchus and lung	3	6	8	3	4
1-035 Malignant melanoma of skin C34	0	0	0	0	0
1-036 Malignant neoplasm of breast	0	0	0	0	0
1-040 Malignant neoplasm of prostate C61	0	1	2	0	0
1-041 Malignant neoplasm of bladder C67	0	0	0	0	0
1-042 Malignant neoplasm of meninges , brain and other parts of central nervous system	24	16	20	13	25
1-043 Non-Hodgkin s lymphoma C82-C85	12	8	11	8	7
1-044 Multiple myeloma and malignant plasma cell neoplasms	1	0	0	0	1
1-045 Leukaemia C91-C95	54	53	52	52	57
1-046 Remainder of malignant neoplasm	47	50	48	35	51
1-047 Remainder of neoplasms D00-D48	2	3	3	3	1
<b>Total</b>	<b>154</b>	<b>148</b>	<b>155</b>	<b>120</b>	<b>150</b>

**Table 31: Distribution of Childhood Cancer related deaths among 0-19 year old females in year 2010-2014**

<b>1-026 Neoplasms C00-D48</b>	<b>2010</b>	<b>2011</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>
1-027 Malignant neoplasm of lip,oral cavity and pharynx	1	2	2	1	2
1-028 Malignant neoplasm of oesophagus C15	1	0	0	1	1
1-029 Malignant neoplasm of stomach C16	1	0	0	0	0
1-030 Malignant neoplasm of colon,rectum and anus C18-C21	0	0	1	0	1
1-031 Malignant neoplasm of liver and intrahepatic bile ducts	2	9	8	1	2
1-032 Malignant neoplasm of pancreas C25	0	0	0	0	1
1-033 Malignant neoplasm of larynx C32	1	2	1	0	0
1-034 Malignant neoplasm of trachea, bronchus and lung	2	1	1	1	4
1-035 Malignant melanoma of skin C34	0	0	0	0	0
1-036 Malignant neoplasm of breast	0	0	0	0	2
1-037 Malignant neoplasm of cervix uteri C53	0	0	0	1	1
1-038 Malignant neoplasm of other and unspecified parts of uterus	1	0	0	0	0
1-039 Malignant neoplasm of ovary C56	3	1	1	1	1
1-041 Malignant neoplasm of bladder C67	1	0	0	0	0
1-042 Malignant neoplasm of meninges, brain and other parts of central nervous system	22	28	24	20	20
1-043 Non-Hodgkin s lymphoma C82-C85	4	7	7	8	3
1-044 Multiple myeloma and malignant plasma cell neoplasms	0	0	0	0	0
1-045 Leukaemia C91-C95	42	40	37	37	22
1-046 Remainder of malignant neoplasm	38	33	34	30	29
1-047 Remainder of neoplasms D00-D48	1	5	4	2	0
<b>Total</b>	<b>120</b>	<b>128</b>	<b>120</b>	<b>103</b>	<b>119</b>




Figure 23: Crude mortality rate for childhood cancer deaths by sex among 0-19 year patients in Sri Lanka 2010 -2014




Figure 24: Age standardized mortality rate for childhood cancer deaths by sex among 0-19 year patients in Sri Lanka 2010 - 2014

## Way Forward

- Establish hospital-based childhood cancer registry including treatment, outcome, follow up and survival details at the National Cancer Institute of Sri Lanka (NCISL)  
*(Already Hospital Based Cancer Registry is commenced using SJCARES software of the St. Jude Global alliance)*
- Establish a mechanism to share relevant data of the hospital-based childhood and adolescent cancer registry at the NCISL with the National Cancer Registry Programme of Sri Lanka
- Commence Population-Based Cancer Registry of Childhood Cancers in Colombo district utilizing existing population based cancer registry infrastructure and analyzing data using International Classification of Childhood Cancer, Third edition (ICCC-3) in par with Global Initiative of Childhood Cancer Registries (Child GICR)
- Improve the section of childhood & adolescent cancer incidence & mortality data with additional outputs in the National Cancer Registry Programme towards developing 'National Population Based Childhood Cancer Registry'
- Strengthen the Civil Registration System to generate timely comprehensive National Childhood Cancer Mortality Data

## References

Cancer Incidence & Mortality Data, National Cancer Control Programme, Ministry of Health Sri Lanka *publications from 1985- 2019 (21 publications)*

<https://www.nccp.health.gov.lk/en/incidenceData>

Department of Census & Statistics of Sri Lanka (2021) Retrieved 15 October 2021 from

<http://www.statistics.gov.lk/Population/StaticalInformation/VitalStatistics> .

Eva Steliarova-Foucher, Murielle Colombet, Lynn A G Ries, Florencia Moreno, Anastasia Dolya, Freddie Bray, Peter Hesselning, Hee Young Shin, Charles A Stiller 'International incidence of childhood cancer, 2001–10: a population-based registry study', *Lancet Oncology* 2017 June Vol 18 pg. 719-731

Global Initiative of Childhood Cancer Registries (Child GICR) Retrieved 15 October 2021 from

<https://gicr.iarc.fr/child-gicr/objectives/>

International Classification of Childhood Cancer, Third Edition, *Cancer* 2005: 103: 1457-67

Marion Pineros, Les Mery, Isabelle Soerjomataram, Freddie Bray, Eva Steliarova-Foucher, Scaling Up the Surveillance of Childhood Cancer: A Global Roadmap *JNCI J Natl Cancer Inst* (2021) 113(1)

Population Based Cancer Registry of Colombo district National Cancer Control Programme, Ministry of Health Sri Lanka *publications from 2012-2019 ( 2 publications)*

<https://www.nccp.health.gov.lk/en/populationBasedColombo>



**National Cancer Control Programme  
Ministry of Health**

555/5, Public Health Complex,  
Elvitigala Mawatha,  
Narahenpita, Colombo 05,  
Sri Lanka.  
Tel: +94 112 368 627  
<http://www.nccp.health.gov.lk>

ISBN 978-624-5719-21-1

